Report on Limited Review of Almirall, S.A. and subsidiaries

(Together with the condensed consolidated interim financial statements and the consolidated interim directors' report of Almirall, S.A. and subsidiaries for the six-month period ended 30 June 2024)

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

KPMG Auditores, S.L.
Torre Realia
Plaça d'Europa, 41-43
08908 L'Hospitalet de Llobregat
(Barcelona)

Report on Limited Review of Condensed Consolidated Interim Financial Statements

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

To the Shareholders of Almirall, S.A. commissioned by the Board of Directors

REPORT ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Introduction

We have carried out a limited review of the accompanying condensed consolidated interim financial statements (the "interim financial statements") of Almirall, S.A. (the "Company") and subsidiaries (together the "Group"), which comprise the balance sheet at 30 June 2024, and the income statement, statement of comprehensive income, statement of changes in equity and statement of cash flows for the six-month period then ended, and explanatory notes (all condensed, consolidated and interim). The Directors of the Company are responsible for the preparation of these interim financial statements in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting as adopted by the European Union, pursuant to article 12 of Royal Decree 1362/2007 as regards the preparation of condensed interim financial information. Our responsibility is to express a conclusion on these interim financial statements based on our limited review.

Scope of Review

We conducted our limited review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A limited review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A limited review is substantially less in scope than an audit conducted in accordance with prevailing legislation regulating the audit of accounts in Spain and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on the accompanying interim financial statements.

(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)

Conclusion

Based on our limited review, which can under no circumstances be considered an audit, nothing has come to our attention that causes us to believe that the accompanying interim financial statements for the six-month period ended 30 June 2024 have not been prepared, in all material respects, in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting as adopted by the European Union, pursuant to article 12 of Royal Decree 1362/2007 as regards the preparation of condensed interim financial statements.

Emphasis of Matter

We draw your attention to the accompanying note 2, which states that these interim financial statements do not include all the information that would be required in a complete set of consolidated financial statements prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The accompanying interim financial statements should therefore be read in conjunction with the Group's consolidated annual accounts for the year ended 31 December 2023. This matter does not modify our conclusion.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

The accompanying consolidated interim directors' report for the six-month period ended 30 June 2024 contains such explanations as the Directors of the Company consider relevant with respect to the significant events that have taken place in this period and their effect on the interim financial statements, as well as the disclosures required by article 15 of Royal Decree 1362/2007. The consolidated interim directors' report is not an integral part of the interim financial statements. We have verified that the accounting information contained therein is consistent with that disclosed in the interim financial statements for the six-month period ended 30 June 2024. Our work is limited to the verification of the consolidated interim directors' report within the scope described in this paragraph and does not include a review of information other than that obtained from the accounting records of Almirall, S.A. and subsidiaries.

Other Matter

This report has been prepared at the request of the Company's Board of Directors in relation to the publication of the half-yearly financial report required by article 100 of Law 6/2023 of 17 March 2023 on Securities Markets and Investment Services.

KPMG Auditores, S.L.

(Signed on original in Spanish)

Juan Ramón Aceytuno Mas

19 July 2024

Almirall, S.A. and Subsidiaries
(Almirall Group)

Condensed Consolidated Interim Financial Statements and Consolidated Interim Management Report for the six-month period ending 30 June 2024

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Condensed consolidated interim balance sheet as at 30 June 2024

(Thousands of euros)

ASSETS	Note	30/06/2024	31/12/2023
		Unaudited	Audited
Goodwill	8	315,966	315,966
Intangible assets	9	928,067	951,415
Right-of-use assets	10	44,626	43,016
Property, plant and equipment	11	141,046	141,287
Financial assets	12	19,603	22,878
Deferred tax assets	23	178,841	181,761
NON-CURRENT ASSETS		**1,628,149**	**1,656,323**
Stocks	14	166,880	167,528
Trade and other receivables	15	158,150	131,498
Current tax assets	23	19,995	15,536
Other current assets		17,337	16,010
Current financial investments	12	1,468	136
Cash and cash equivalents	13	329,407	387,954
CURRENT ASSETS		**693,237**	**718,662**
TOTAL ASSETS		**2,321,386**	**2,374,985**

LIABILITIES AND EQUITY	Note	30/06/2024	31/12/2023
		Unaudited	Audited
Subscribed capital	16	25,616	25,127
Share premium	16	581,874	545,866
Legal reserve	16	4,275	4,275
Other reserves	16	837,939	915,984
Valuation adjustments and other adjustments	16	(30,511)	(33,205)
Translation differences	16	51,989	43,827
Profit for the year		15,390	(38,474)
EQUITY		**1,486,572**	**1,463,400**
Deferred income	17	4,321	-
Financial liabilities	18	337,422	341,851
Non-current liabilities from leasing	10	38,819	37,605
Deferred tax liabilities	23	67,927	71,920
Retirement benefit obligations	20	56,634	60,481
Provisions	21	14,031	13,926
Other non-current liabilities	19	41,650	34,727
NON-CURRENT LIABILITIES		**560,804**	**560,510**
Financial liabilities	18	12,309	13,968
Current liabilities for leasing	10	6,528	6,206
Trade payables	19	182,330	181,354
Current tax liabilities	23	32,951	29,044
Other current liabilities	19	39,892	120,503
CURRENT LIABILITIES		**274,010**	**351,075**
TOTAL LIABILITIES AND EQUITY		**2,321,386**	**2,374,985**

Explanatory Notes 1 to 30 are an integral part of the condensed consolidated interim financial statements for the six-month period ending 30 June 2024.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Condensed consolidated interim income state for the six-month period ending 30 June 2024

(Thousands of euros)

	Note	2024 Period	2023 Period
		Unaudited	Unaudited
Net turnover	22	497,218	466,060
Other Income	22	2,858	1,173
Operating income		**500,076**	**467,233**
Work carried out on fixed assets	9	12,396	3,217
Supplies	22	(119,328)	(115,147)
Staff costs	22	(118,110)	(107,009)
Depreciation	9, 10 & 11	(68,601)	(62,830)
Net change in valuation adjustments		(1,275)	(310)
Other operating expenses	22	(169,277)	(146,278)
Net gains (losses) on disposal of assets	22	(3,171)	-
Operating profit		**32,710**	**38,876**
Financial income	22	3,749	1,085
Financial expenses	22	(8,037)	(7,388)
Exchange rate differences	22	(598)	(771)
Gains / (losses) on measurement of financial instruments	18 & 22	2,448	(3,679)
Financial result		**(2,438)**	**(10,753)**
Earnings before tax		**30,272**	**28,123**
Corporate income tax		(14,882)	(16,108)
Net profit for the period attributable to the Parent Company		**15,390**	**12,015**
Earnings / (Loss) per Share (Euros):	26		
A) Basic		0.07	0.06
B) Diluted		0.07	0.06

Explanatory Notes 1 to 30 are an integral part of the condensed consolidated interim financial statements for the six-month period ending 30 June 2024.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Condensed consolidated interim statement of comprehensive income for the six-month period ending 30 June 2024

(Thousands of euros)

		2024 Period	2023 Period
	Note	**Unaudited**	**Unaudited**
Result for the period		**15,390**	**12,015**
Other comprehensive income:			
Items not to be reclassified to income			
Retirement benefit obligations	20	3,742	-
Income tax on items that will not be reclassified	23	(1,048)	-
Others		-	-
Total items not to be reclassified to income		**2,694**	**-**
Items that can be reclassified subsequently to profit or loss			
Other changes in value		-	-
Foreign currency translation differences	16	8,162	(5,029)
Total items that can be reclassified subsequently to profit or loss		**8,162**	**(5,029)**
Other comprehensive income for the period, net of tax		**10,856**	**(5,029)**
Total comprehensive income for the period		**26,246**	**6,986**
Attributable to:			
- Owners of the parent company		26,246	6,986
- Non-controlling interests		-	-
Total comprehensive income attributable to owners of the parent company derived from:			
- Continuing operations		26,246	6,986
- Discontinued operations		-	-

Explanatory Notes 1 to 30 are an integral part of the condensed consolidated interim financial statements for the six-month period ending 30 June 2024**.**

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Condensed consolidated interim statement of changes in equity
for the six-month period ending 30 June 2024

(Thousands of euros)

					Other reserves			Other comprehensive income			
	Note	**Subscribed capital**	**Share premium**	**Legal reserve**	**Other reserves of the Parent Company**	**Treasury shares of the Parent Company**	**Consolidated reserves**	**Valuation adjustments to equity**	**Translation differences**	**Profit attributable to the Parent Company**	**Equity**
Balance as at 01 January 2023	**16**	**21,782**	**317,315**	**4,275**	**955,022**	**(2,552)**	**(4,299)**	**(28,635)**	**51,526**	**4,281**	**1,318,715**
Distribution of profits		-	-	-	(57,667)	-	61,948	-	-	(4,281)	-
Capital increase	16	2,927	197,073	-	-	-	-	-	-	-	200,000
Capital increase costs	16	-	-	-	(1,674)	-	-	-	-	-	(1,674)
Dividends	25	418	31,478	-	(34,488)	-	-	-	-	-	(2,592)
Treasury shares of the Parent Company	16	-	-	-	-	(165)	-	-	-	-	(165)
Total comprehensive income for the period		-	-	-	-	-	-	-	(5,029)	12,015	6,986
Balance as at 30 June 2023 (unaudited)	**16**	**25,127**	**545,866**	**4,275**	**861,193**	**(2,717)**	**57,649**	**(28,635)**	**46,497**	**12,015**	**1,521,270**

					Other reserves			Other comprehensive income			
	Note	**Subscribed capital**	**Share premium**	**Legal reserve**	**Other reserves of the Parent Company**	**Treasury shares of the Parent Company**	**Consolidated reserves**	**Valuation adjustments to equity**	**Translation differences**	**Profit attributable to the Parent Company**	**Equity**
Balance as at 01 January 2024	**16**	**25,127**	**545,866**	**4,275**	**861,193**	**(2,858)**	**57,649**	**(33,205)**	**43,827**	**(38,474)**	**1,463,400**
Distribution of profits		-	-	-	(60,154)	-	21,680	-	-	38,474	-
Dividends	25	489	36,008	-	(39,785)	-	-	-	-	-	(3,288)
Treasury shares of the Parent Company	16	-	-	-	-	214	-	-	-	-	214
Total comprehensive income for the period		-	-	-	-	-	-	2,694	8,162	15,390	26,246
Balance as at 30 June 2024 (unaudited)	**16**	**25,616**	**581,874**	**4,275**	**761,254**	**(2,644)**	**79,329**	**(30,511)**	**51,989**	**15,390**	**1,486,572**

Explanatory Notes 1 to 30 are an integral part of the condensed consolidated interim financial statements for the six-month period ending 30 June 2024.

(Translation of a report originally issued in Spanish. In the event of discrepancy, the Spanish language version prevails)

Almirall, S.A. and Subsidiaries (Almirall Group)

Condensed consolidated interim cash flow statement for the six-month period ending 30 June 2024 (indirect method)

(Thousands of euros)

	Note	2024 Period	2023 Period
		Unaudited	
Cash Flow			
Earnings before tax		30,272	28,123
Depreciation	9, 10 & 11	68,601	62,830
Net gains (losses) on disposal of assets	22	3,171	-
Financial income	22	(3,749)	(1,085)
Financial expenses	22	8,037	7,388
Exchange rate differences	22	598	771
Changes in fair value of financial instruments	18 & 22	(2,448)	3,679
Allocation of government grants to results	17	(857)	-
Change in fair value of Covis Pharma financial assets	12 & 22	(518)	(704)
		103,107	**101,002**
Adjustments for changes in working capital:			
Change in stocks	14	715	(14,432)
Change in trade and other receivables	15	(16,557)	(6,812)
Change in trade payables	19	1,029	2,913
Change in other current assets		986	(4,476)
Change in other current liabilities		(6,149)	(6,074)
Adjustments for changes in other non-current items:			
Other non-current assets and liabilities		1,651	(1,598)
		(18,325)	**(30,479)**
Cash flow from taxes:		**(18,468)**	**(13,415)**
Net cash flows from operating activities (I)		**66,314**	**57,108**
Cash flow from investment activities			
Interest received		3,034	413
Investments:			
Intangible assets	9 & 19	(110,352)	(50,515)
Property, plant and equipment	11	(9,164)	(10,602)
Financial assets	12 & 13	(50,369)	(130,000)
Divestments:			
Receivables linked to the contract with Covis/AstraZeneca	12	7,875	19,977
Property, plant and equipment	11	751	-
Net cash flows from investment activities (II)		**(158,225)**	**(170,727)**
Cash flow from financing activities			
Interest payable	18	(4,995)	(5,244)
Equity instruments:			
Capital increase	16	-	197,768
Dividends paid	25	(3,288)	(2,592)
Acquisition/Disposal of own equity instruments	16	214	(165)
Financial instruments:			
Repayment of debts with credit institutions	18	(5,000)	(5,000)
Finance lease payments	10	(4,306)	(3,342)
Others		739	462
Net cash flows from financing activities (III)		**(16,636)**	**181,887**
Net change in cash and cash equivalents (I+II+III)		**(108,547)**	**68,268**
Cash and cash equivalents at the start of the reporting period	**13**	**387,954**	**248,823**
Cash and cash equivalents at the end of the reporting period	**13**	**279,407**	**317,091**

Explanatory Notes 1 to 30 are an integral part of the condensed consolidated interim financial statements for the six-month period ending 30 June 2024.

1. General information

Almirall, S.A. (hereinafter, the Company or Parent Company) is the parent company of a Group of companies (hereinafter, the Group), the corporate purpose of which consists basically in the purchase, manufacture, storage, marketing and mediation in the sale of pharmaceutical specialities and products, as well as of all types of raw materials used in the preparation of such pharmaceutical specialities and products.

Accordingly, the Parent Company's corporate purpose also includes:

a) The purchase, manufacture, storage, marketing, and mediation in the sale of cosmetics and of chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use, as well as of all kinds of instruments, complements and accessories for the chemical, pharmaceutical and clinical industry.

b) Research on active chemical and pharmaceutical ingredients and products.

c) The purchase, sale, rental, subdivision, and development of plots, land and estates of any nature, with the option of choosing to build on or dispose of these, in full, in part, or under the horizontal property regime.

d) The provision of prevention services for the undertakings and companies participating in the company pursuant to Art. 15 of Royal Decree 39/1997, of 17 January, which establishes the Prevention Services Regulations, and implementing regulations. This activity may be regulated and carried out jointly for related and participating companies of the Parent Company pursuant to Art. 21 of the aforementioned legal text. It is expressly stated that, according to the law, this activity does not require administrative authorisation. According to Article 15 of Royal Decree 39/1997, this activity may be subcontracted to other specialised entities.

e) To direct and manage the Company's participation in the share capital of other entities through the appropriate organisation of human and material resources.

Pursuant to the Parent Company's articles of association, the aforementioned corporate purpose may be pursued, in whole or in part, directly by the Parent Company itself or indirectly through shareholding or equity interests, or any other rights or interests in companies or other types of entities, with or without legal personality, with registered office in Spain or abroad, which engage in activities identical or similar to those included in the corporate purpose of the Parent Company.

Almirall, S.A., which is listed on the Spanish Stock Exchanges included in the Stock Exchange Interconnection System (continuous market), has its registered office and head office at Ronda General Mitre, 151, Barcelona (Spain).

2. Basic principles of presentation

a) Regulatory framework of financial reporting applied to the Group

In accordance with Regulation (EC) no. 1606/2002 of the European Parliament and of the Council of 19 July 2002, all companies governed by the law of a European Union member state and whose securities are listed on a regulated market of one of the member states must present their consolidated annual accounts for the years beginning on or after 1 January 2005 in accordance with the International Financial Reporting Standards previously adopted by the European Union (hereinafter, EU-IFRSs).

These condensed consolidated interim financial statements, prepared by the directors of Almirall, S.A. on 19 July 2024, are presented in accordance with IAS 34 and Article 12 of Royal Decree 1362/2007.

Pursuant to IAS 34, the Interim Financial Information is prepared solely with the intention of updating the content of the latest consolidated financial statements prepared by the directors of the Parent Company and approved at the General Meeting held on 10 May 2024, with emphasis on new activities, events and circumstances that have occurred during the six-month period, without duplicating the information previously published in the consolidated financial statements for the financial year ending 31 December 2023. Therefore, for a proper understanding of the information included in these condensed consolidated interim financial statements, they should be read in conjunction with the Group's consolidated financial statements for FY 2023, prepared in accordance with EU-IFRS.

b) Comparability of the information

The information contained in these condensed consolidated interim financial statements for the first half of the financial year 2023 and/or as at 31 December 2023 is presented solely and exclusively for purposes of comparison with the information for the six-month period ending 30 June 2024.

These accounting statements included in the present condensed consolidated interim financial statements have been prepared following the same criteria as the comparative periods as at 30 June 2023 and/or as at 31 December 2023. There have been no significant changes in the composition of the Group that would significantly affect the comparability of the consolidated balance sheet figures as at 30 June 2024 with those as at 31 December 2023, as well as those in the consolidated interim income statement for the six-month period ending 30 June 2024 with those for the six-month period ending 30 June 2023.

3. Accounting policies

The accounting policies, accounting methods and consolidation principles used in the preparation of these condensed consolidated interim financial statements are the same as those applied in the consolidated financial statements for the year ending 31 December 2023, except for the following standards and interpretations that became effective during the first half of 2024:

Standards, amendments and interpretations are mandatory for all fiscal years beginning on or after 1 January 2024:

- Classification of Liabilities as Current or Non-current – Amendment to IAS 1.
- Lease Liability in a Sale and Leaseback – Amendments to IFRS 16.
- Non-current Liabilities with Covenants – Amendments to IAS 1.
- Supplier Finance Arrangements – Amendments to IAS 7 and IFRS 7.
- International Tax Reform – Pillar Two Model Rules – Amendments to IAS 12.

At the preparation date of these condensed consolidated interim financial statements, the IASB and the IFRS Interpretations Committee had published the following standards, amendments and interpretations, pending adoption by the European Union:

Standards, amendments and interpretations that have not yet entered into force but may be adopted in advance:

- Absence of Convertibility – Amendments to IAS 21, effective 1 January 2025.
- Classification and Measurement of Financial Assets – Amendments to IFRS 9 and IFRS 7, effective 1 January 2026.
- IFRS 19 Subsidiaries without Public Accountability: Disclosures, effective 1 January 2027.

Standards, amendments and interpretations of existing standards that cannot be adopted in advance or have not been adopted by the European Union.

- IFRS 18 Presentation and Disclosure in Financial Statements

The Group has not considered the early application of the Standards and interpretations detailed above, and in any case, the Group is analysing the impact that these new standards/amendments/interpretations may have on the Group's consolidated financial statements, should they be adopted by the European Union, although it considers that their application will not have a significant impact.

4. Estimates

The consolidated results and the determination of consolidated equity are sensitive to the accounting principles and policies, estimates and assessment criteria used to prepare these condensed consolidated interim financial statements. The principal accounting policies and measurement bases are disclosed in Note 5 to the latest consolidated financial statements for 2023. Likewise, in relation to critical accounting judgements and estimates, the same criteria have been applied as those indicated in Note 7 to the latest consolidated financial statements for the year ending 31 December 2023, with no changes that have a significant effect on these condensed consolidated interim financial statements.

In these financial statements, estimates made by the Group's management and ratified by the Parent Company's directors have been used to quantify certain assets, liabilities, income, expenses and commitments. Basically, these estimates refer to:

- Impairment losses on certain goodwill, intangible assets and property, plant and equipment arising from the non-recoverability of the carrying amount recorded for such assets (Notes 8, 9 and 11).
- The useful life of intangible assets and of property, plant and equipment (Notes 9 and 11).
- The evaluation of the recoverability of deferred tax assets (Note 23).
- The fair value of certain unquoted financial assets (Note 12).
- Precise assumptions for determination of the actuarial liability for the retirement benefit obligations in coordination with an independent expert (Note 20).
- The income tax expense, which, in accordance with IAS 34, is recognised in interim periods on the basis of the best estimate of the weighted average tax rate that the Group expects for the annual period.

Although the estimates described above were made on the basis of the best information available to date on the events analysed, events that take place in the future might make it necessary to change these estimates (upwards or downwards) at the close of the six-month period ending 30 June 2024, or in subsequent financial years, which, if necessary and in accordance with IAS 8, would be done prospectively, recognising the effects of the change in estimate in the consolidated income statement for the years affected.

During the six months ending 30 June 2024, there have been no significant changes to the estimates made at the end of 2023.

5. Financial risk management

The Group's activities are exposed to different financial risks: mainly market risk (including exchange rate risk, interest rate risk and price risk), credit risk and liquidity risk.

There have been no significant changes in the risk management department or in any risk management policy since the end of the previous year.

6. Other information

a) Contingent assets and liabilities

Information on contingent assets and liabilities as at 30 June 2024 is provided in Note 27 of the explanatory notes to the accompanying condensed consolidated interim financial statements.

b) Seasonality of the Group's transactions

The seasonality of the operations carried out by the Group, basically related to the supply of pharmaceuticals, is inherent in the nature of the products supplied insofar as the accumulation of these products by customers is not distributed in a linear fashion over the annual periods. The main reason for this is the different development over time of certain diseases and/or conditions.

c) Relative importance

In determining the information to be disclosed in the explanatory notes on the different items of the financial statements or other matters, the Group, in accordance with IAS 34, has taken into account the relative importance in relation to these condensed consolidated interim financial statements.

d) Condensed consolidated interim cash flow statement

The following expressions are used in the condensed consolidated interim cash flow statement with the following meanings:

- Cash flows are the inflows and outflows of cash and cash equivalents.
- Operating activities are the activities that constitute the main source of the entity's ordinary income, as well as other activities that cannot be classified as investing or financing activities.
- Investment activities are the acquisition and disposal of long-term assets, as well as other investments not included in cash and cash equivalents.
- Financing activities are activities that result in changes to the size and composition of the Group's equity and borrowings.

In the Consolidated Balance Sheet and also for purposes of the Consolidated Cash Flow Statement, cash on deposit with the Group is classified as "Cash and other liquid assets" and consists mainly of:

- Current accounts
- Bank demand deposits
- Highly liquid short-term financial investments without market risk, with a maturity of less than three months as from the date of acquisition and without significant penalties in the event of early cancellation.

e) Changes in the composition of the Group

During the six-month period ending 30 June 2024, there has been no change in the composition of the Group with respect to 31 December 2023.

7. Business combination

During the six months ending 30 June 2024, there have been no business combinations.

8. Goodwill

The composition of this heading in the condensed consolidated interim balance sheet is as follows:

	Thousands of Euros	
	30/06/2024	**31/12/2023**
Almirall, S.A.	35,407	35,407
Almirall Hermal GmbH	227,743	227,743
Poli Group	52,816	52,816
Total	**315,966**	**315,966**

There have been no changes in the composition of goodwill from that described in the consolidated financial statements for the year ending 31 December 2023.

Impairment losses

No impairment has been recorded in the six months ending 30 June 2024.

As of 30 June 2024, there has been no significant change in the key assumptions on which Management has based its determination of the recoverable amount of the cash-generating units to which the previous goodwill is assigned, nor has there been any indication of impairment or change in the sensitivity analyses in relation with Note 5-d to the consolidated financial statements for the year ending 31 December 2023. Therefore, the Management has not updated any impairment calculation for these units for the interim closing date of 30 June 2024.

9. Intangible assets

The composition of and movement in this heading of the condensed consolidated interim balance sheet during the six-month period ending 30 June 2024 was as follows:

Thousands of euros	Balance as at 31 December 2023	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 30 June 2024
Industrial property	2,102,789	150	-	(5,643)	18,478	2,115,774
Development costs[1]	87,997	12,396	-	-	505	100,898
Computer applications	103,326	821	4,713	(44)	44	108,860
Advances and property, plant and equipment in progress	55,049	15,851	(4,713)	(1,713)	-	64,474
Total cost Intangible Assets	2,349,161	29,218	-	(7,400)	19,027	2,390,006
Accum. A. Industrial property	(1,013,911)	(52,489)	-	4,939	(8,458)	(1,069,919)
Accum. A. Development costs	(2,246)	(540)	-	-	-	(2,786)
Accum. A. Computer applications	(85,663)	(3,748)	-	34	(31)	(89,408)
Total Accum. A. Intangible assets	(1,101,820)	(56,777)	-	4,973	(8,489)	(1,162,113)
Impairment losses	(295,926)	-	-	-	(3,900)	(299,826)
Net Value Intangible assets	**951,415**	**(27,559)**	**-**	**(2,427)**	**6,638**	**928,067**

[1] Additions to the Development Expenses heading correspond to expenses generated internally in the six-month period ending 30 June 2024.

The intangible assets described in the table above have finite useful lives, and the majority of them have been acquired from third parties or as part of a business combination, with the exception of the internally generated development costs described further below in this Note. There are no assets subject to debt guarantees.

During the first six months of 2024, additions of intangible assets amounted to €29.2 million and mainly reflect the following circumstances:

- In February 2024, a development and licensing agreement was signed with Novo Nordisk for the rights to NN-8828 for the use thereof in various fields, including immune-mediated inflammatory skin diseases. NN-8828 is an IL-21 blocker that inhibits IL-21-induced pathophysiological functions in several immunomodulatory diseases. Under the terms of this agreement, an upfront payment of €10 million was accrued, and the agreement includes various development milestones (up to a maximum of €140 million) and milestones for reaching certain sales thresholds.
- In March 2024, an agreement was signed with Eloxx Pharmaceuticals Inc. for the rights to ZKN-013, including its use in orphan dermatological diseases. ZKN-013 is a potentially promising oral drug for reading nonsense mutations, which allows host cells to produce functional proteins that counteract the root cause of these rare dermatological diseases and potentially others. Under the terms of this agreement, the Group has paid $3 million (equivalent to €2.7 million), and various development and marketing milestones are included, as well as milestones for reaching certain sales thresholds, for a maximum amount of $470 million.
- Following the EMA's approval of Ebglyss in November 2023 (indicated for atopic dermatitis), certain clinical studies related to this product started to be capitalised (mainly a long-term safety study and a study to collect biomarker data with patients from various countries in Europe). The total amount capitalised in the six-month period ending 30 June 2024 amounts to €12.4 million.

The translation differences in the period are mainly due to the evolution of the US dollar exchange rate, mainly linked to the portfolio acquired from Allergan in 2018.

Disposals for the six-month period ending 30 June 2024 are due to termination of the contract with Isolex, which resulted in the write-off of the initial payment made in 2023 (€1.7 million), and due to the discontinuation of one of the products that formed a part of the takeover of Aqua Pharmaceuticals (Altabax), whose net book value amounted to €0.7 million. Both write-offs resulted in a loss of €2.4

million, which was recorded under "Net gains (losses) on disposal of assets" in the condensed interim income statement for the six-month period ending on 30 June 2024 (Note 22).

Impairment losses

During the six months ending 30 June 2024, there have been no significant changes to the estimates made at the end of 2023.

A sensitivity analysis conducted on the assets that were impaired as at 31 December 2023 (the Seysara product, which forms a part of the "Allergan portfolio" CGU) is included below, updated for reasonably possible variations in the main key assumptions:

Cash Generating Units or intangible asset	Sensitivity analysis	Impact on impairment value (millions of euros)
Allergan portfolio	- Increase / Reduction of the estimated sales volume by 10% (*) - Increase / Reduction of five points in the growth rate. - Half-point increase/decrease in discount rate	+15 / (25) +3 / (13) (6) / +3

(*) Sales volume and costs directly associated with this volume

10. Right-of-use assets

The composition of and movement in this heading of the condensed consolidated interim balance sheet during the six months ending 30 June 2024 was as follows:

Thousands of euros	Balance as at 31 December 2023	Recognitions	Derecognitions	Translation differences	Balance as at 30 June 2024
Construction	56,820	4,490	(2,803)	21	58,528
Machinery	137	-	-	-	137
Transport equipment	9,976	763	(923)	7	9,823
Total cost Rights of use	66,933	5,253	(3,726)	28	68,488
Accum. A. Construction	(19,117)	(2,425)	2,803	11	(18,728)
Accum. A. Machinery	(43)	(22)	-	-	(65)
Accum. A. Transport equipment	(4,757)	(1,237)	923	2	(5,069)
Total Accum. A. Rights of use	(23,917)	(3,684)	3,726	13	(23,862)
Net Value Rights of use	**43,016**	**1,569**	**-**	**41**	**44,626**

The additions for the six-month period ending 30 June 2024 mainly relate to the signing of a new contract for the offices of the subsidiary Almirall SaS (France) for a period of 9 years.

The main asset refers to the lease of the Group's headquarters (Note 28), with a net carrying amount of €31.3 million as at 30 June 2024. There are no other contracts that are individually relevant.

Lease payments made during this period amounted to €4,306 thousand.

Details of lease liabilities are as follows, together with their maturities:

	Balance as at 30 June 2024	Balance as at 31 December 2023
Liabilities for leasing		
Non-current	38,819	37,605
Current	6,528	6,206
Total	**45,347**	**43,811**

Liabilities for leasing	Maturities	Thousands of Euros
Current	Up to 6 months	3,425
	From 6 months to 1 year	3,103
Non-current	From 1 to 2 years	6,712
	From 2 to 3 years	5,842
	From 3 to 4 years	5,307
	From 4 to 5 years	5,101
	More than 5 years	15,857
Total		**45,347**

11. Property, plant and equipment

The composition of and movement in this heading of the condensed consolidated interim balance sheet during the six months ending 30 June 2024 was as follows:

Thousands of euros	Balance as at 31 December 2023	Recognitions	Transfers	Derecognitions	Translation differences	Balance as at 30 June 2024
Land and construction	96,287	386	902	(1,469)	(5)	96,101
Technical installations and machinery	102,954	1,272	1,807	-	6	106,039
Other facilities, tools and furnishings	252,333	2,674	8,613	(150)	39	263,509
Other property, plant and equipment	20,066	564	300	(405)	45	20,570
Advances and property, plant and equipment in progress	32,661	4,268	(11,622)	-	160	25,467
Total cost Property, plant and equipment	504,301	9,164	-	(2,024)	245	511,686
Accum. A. Land and construction	(53,779)	(1,117)	-	-	(1)	(54,897)
Accum. A. Technical installations and machinery	(65,830)	(1,928)	-	-	-	(67,758)
Accum. A. Other facilities, tools and furnishings	(226,551)	(4,253)	-	125	(13)	(230,692)
Accum. A. Other property, plant and equipment	(16,854)	(842)	-	404	(1)	(17,293)
Total Accum. A. Property, plant and equipment	(363,014)	(8,140)	-	529	(15)	(370,640)
Impairment losses	-	-	-	-	-	-
Net value Property, plant and equipment	**141,287**	**1,024**	**-**	**(1,495)**	**230**	**141,046**

The additions for the six-month period ending 30 June 2024 are mainly due to upgrades at the production facilities of the Group's pharmaceutical plants.

Disposals in the six-month period ending 30 June 2024 are mainly due to the sale of land located in Sant Joan Despí (Barcelona) for the amount of €750 thousand, whose net book value amounted to €1,475 thousand. The resulting net loss (€725 thousand) was recognised under "Net gains (losses) on disposal of assets" in the condensed consolidated interim income statement for the six-month period ending 30 June 2024 (Note 22).

12. Financial assets

As detailed in Note 5-i) to the consolidated financial statements for the year ending 31 December 2023, the Group classifies its financial assets into the following valuation categories:

- Financial assets measured at fair value through profit or loss: these assets do not meet the criteria for classification at amortised cost in accordance with IFRS 9 because their cash flows do not only represent payments of principal and interest. Consequently, this heading includes not only the balances receivable arising from recognition of the sale of the respiratory business in 2014, as explained below in this Note (agreement with Covis), but also the derivative financial instruments that do not qualify for hedge accounting.
- Financial assets measured at fair value through other comprehensive income: this heading includes equity instruments over which the Group does not have control, wherefore they are not

included within the scope of consolidation. As of 30 June 2024 and 31 December 2023, there are no such instruments.

- Financial assets valued at amortised cost: this heading includes fixed-income investments made through deposits with maturities of less than one year, mainly in euros, although they may occasionally be in foreign currencies in the event of a surplus (normally dollars). At the date of initial application, the Group's business model is to hold these investments in order to receive contractual cash flows that only represent payments of principal and interest on the principal amount.

Non-current financial investments

The composition of and movement in this heading of the condensed consolidated interim balance sheet during the six months ending 30 June 2024 was as follows:

Thousands of euros	Balance as at 31 December 2023	Recognitions	Changes in fair value	Transfers	Derecognitions	Translation differences	Balance as at 30 June 2024
Fair value through profit or loss	20,893	-	518	(3,988)	-	-	17,423
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	8,602	169	-	-	-	239	9,010
Total cost	29,495	169	518	(3,988)	-	239	26,433
Fair value through profit or loss	-	-	-	-	-	-	-
Fair value, changes in equity	-	-	-	-	-	-	-
Amortised cost	(6,617)	-	-	-	-	(213)	(6,830)
Total impairment	(6,617)	-	-	-	-	(213)	(6,830)
Net Value	**22,878**	**169**	**518**	**(3,988)**	**-**	**26**	**19,603**

- Assets at fair value through profit or loss

Assets at fair value through profit or loss consist entirely of the financial asset linked to the agreement with Covis. This asset originated in November 2014 when the Group transferred to AstraZeneca the rights to part of its respiratory franchise (Eklira and Duaklir, and other brands with the compound aclidinium bromide), which included several components that involved receiving cash and deferred payments based on certain future milestones. On 5 January 2022, the agreement between AstraZeneca and Covis for the transfer of these rights entered into force. At 30 June 2024 and 31 December 2023, the remaining amount receivable consists entirely of the net present value of royalties receivable from 2025 onwards. The royalties receivable in the upcoming 12 months are classified under the heading "Trade and other receivables".

Note 12 of the notes to the consolidated annual accounts for the year ended 31 December 2023 explains the fair value calculation methodology and the main assumptions for the valuation thereof. Changes in the fair value of this financial asset are recorded under the heading "Other income" in the consolidated income statement (Note 22).

The changes of these assets in the condensed consolidated interim balance sheet and the cash flows that have occurred, as shown in detail in the condensed consolidated interim cash flow statement, are detailed below:

Thousands of euros	Balance as at 31 December 2023	Changes in fair value	Transfers	Cash Flow	Balance as at 30 June 2024
Non-current financial assets (Note 12)	20,893	518	(3,988)	-	17,423
Trade and other receivables (Note 15)	13,198	-	3,988	(7,875)	9,311
Total	**34,091**	**518**	**-**	**(7,875)**	**26,734**

- Assets at amortised cost

Assets at amortised cost mainly consist of long-term deposits. As at 30 June 2024 and 31 December 2023, there are loans to the company to which the subsidiary ThermiGen LLC was sold in 2021. (Celling Aesthetics LLC and other related companies), which are fully impaired.

Current financial investments

At 30 June 2024 and 31 December 2023, this heading mainly includes accrued interest receivable and short-term guarantees. In the case of short-term investments that do not meet the criteria to be considered cash equivalents (Note 13), they are classified under this heading. Investments made during the six-month period ending 30 June 2024 earned an average interest rate of 3.9%.

13. Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits with banks and other short-term, highly liquid investments with an original maturity of three months or less.

For the purposes of the cash flow statement, this criterion is maintained as long as those deposits do not have significant penalties for early cancellation (otherwise they are treated as an investment). As at 30 June 2024 there are deposits amounting to €50 million that have been classified in the flow from investment activities. The following table shows the reconciliation between the cash shown in the Consolidated Balance Sheet and the cash shown in the Consolidated Cash Flow Statement:

	Thousands of Euros	
	30/06/2024	**31/12/2023**
Balance Sheet	**329,407**	**387,954**
Investments with a term of less than 3 months with penalties	(50,000)	-
Cash Flow Statement	**279,407**	**387,954**

The bank accounts are interest-bearing, with average interest accruing at 1.0% during the six-month period ending 30 June 2024.

14. Stocks

The itemisation of this heading in the condensed consolidated interim balance sheet on 30 June 2024 and 31 December 2023 is as follows:

	Thousands of Euros	
	30/06/2024	**31/12/2023**
Raw materials and packaging materials	46,374	51,702
Semi-finished products	27,069	23,280
Goods	15,250	14,711
Finished products	78,102	77,677
Advances to suppliers	85	158
Total	**166,880**	**167,528**

The balance of inventories in the preceding table is presented net of balances impaired due to obsolescence and slow turnover, which, at 30 June 2024 and 31 December 2023, amounts to €15.2 million and €12.9 million, respectively.

There are no stocks subject to warranty, and there are no commitments to purchase stock worthy of note.

15. Trade and other receivables

The itemisation of this heading in the condensed consolidated interim balance sheet on 30 June 2024 and 31 December 2023 is as follows:

	Thousands of Euros	
	30/06/2024	31/12/2023
Trade receivables for sales and services	130,013	109,005
Receivable from Covis Pharma (Note 12)	9,311	13,198
Other receivables	22,111	11,480
Provision for impairment losses	(3,285)	(2,185)
Total	**158,150**	**131,498**

The heading “Other debtors" includes the collection rights of loans granted by the CDTI (Centro para el Desarrollo Tecnológico Industrial, a public business entity in Spain, under the Ministry of Science, Innovation and Universities) at 30 June 2024, linked to the performance of various research and development projects (Note 19).

The balance of the "Provision for impairment losses" includes €1,161 thousand at 30 June 2024 (€411 thousand at 31 December 2023) as a result of applying the "expected loss" model (simplified approach) provided for in IFRS 9.

Itemised below is the balance of receivables according to their maturity as at 30 June 2024 and 31 December 2023:

	Thousands of euros				
	Trade receivables for sales and services	Receivable from Covis Pharma	Other receivables	Valuation adjustments for impairment	Total receivables
Balance as at 30 June 2024	**130,013**	**9,311**	**22,111**	**(3,285)**	**158,150**
Not matured	110,674	9,311	22,111	(1,161)	140,935
Less than 30 days	13,612	-	-	-	13,612
From 30 to 60 days	708	-	-	-	708
From 60 to 90 days	3,855	-	-	(960)	2,895
From 90 to 180 days	492	-	-	(492)	-
From 180 to 360 days	279	-	-	(279)	-
More than 360 days	393	-	-	(393)	-
Balance as at 31 December 2023	**109,005**	**13,198**	**11,480**	**(2,185)**	**131,498**
Not matured	89,694	13,198	11,480	-	114,372
Less than 30 days	12,098	-	-	-	12,098
From 30 to 60 days	3,437	-	-	-	3,437
From 60 to 90 days	1,342	-	-	-	1,342
From 90 to 180 days	1,575	-	-	(1,326)	249
From 180 to 360 days	574	-	-	(574)	-
More than 360 days	285	-	-	(285)	-

There is no concentration of credit risk with respect to trade receivables, since the Group has a large number of customers.

On 30 June 2024, the percentage of balances with Public Administrations for the hospital business out of the total customer balance for sales and services rendered comes to 5.9% (8.2% on 31 December 2023).

There are no guarantees on customer balances.

(Thousands of euros)

Receivables other than financial assets related to Covis Pharma GmbH (Note 12) are stated at nominal value, since there are no significant differences from their fair value.

16. Equity

Share capital

The Parent Company's share capital as at 30 June 2024 is represented by 213,468,718 shares with a par value of €0.12, fully subscribed and paid up (209,393,724 shares as at 31 December 2023).

On 12 June 2024, a total of 4,074,994 new shares from the flexible dividend of the Parent Company were admitted to trading on the Barcelona, Madrid, Bilbao and Valencia stock exchanges. These shares were representative of the holders of 91.5% of the rights to be allotted shares at no charge, who opted to receive new shares instead of cash. Consequently, the share capital of the Parent Company following the bonus issue of shares increased by €488,999.28.

The shareholders with significant holdings in the share capital of Almirall, S.A., both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, according to the information contained in the official records of the National Securities Market Commission (CNMV) as at 30 June 2024 and 31 December 2023, are as follows:

Name or company name of the direct shareholder	**% Interest 30/06/2024**	**% Interest 31/12/2023**
Grupo Plafin, S.A.	44.6%	44.5%
Grupo Corporativo Landon, S.L.	15.7%	15.6%
Norbel Inversiones	5.1%	5.1%
Wellington Management	2.9%	5.0%
Total	**68.3%**	**70.2%**

At 30 June 2024 and 31 December 2023, the Parent Company was not aware of any other holdings equal to or greater than 3% of the share capital or voting rights of the Parent Company, which, although less than the established percentage, would enable the exercise of significant influence over the Parent Company.

Legal reserve

The part of the balance of the legal reserve that exceeds 10% of the previously increased capital may be used for a capital increase. Except for the aforementioned purpose, the legal reserve can only be used to offset losses if no other reserves are available and as long as it does not exceed 20% of the share capital.

The amount of €4,275 thousand present in this account as at 30 June 2024 and 31 December 2023 corresponds to the balance of the Parent Company's legal reserve.

Share premium

The Spanish Capital Companies Act expressly permits the use of the share premium balance to increase capital and does not establish any specific restrictions on the availability of this balance.

As a consequence of the increase in fully-paid share capital resulting from the flexible dividend, this item was increased by the difference between the par value of the shares and the value equivalent to the dividend, which amounts to €36,008 thousand.

After this capital increase, the balance of the share premium item amounted to €581,874 thousand at 30 June 2024 (€545,866 thousand at 31 December 2023).

Other reserves

The itemisation of this heading in the condensed consolidated interim balance sheet is as follows:

	Thousands of euros	
	30/06/2024	**31/12/2023**
Reserves Investments Canary Islands	3,485	3,485
Reserve amortised capital	30,540	30,540
Reserve merger	4,588	4,588
Revaluation reserve	2,539	2,539
Other voluntary reserves	720,102	820,041
Subtotal Other reserves of the Parent Company	**761,254**	**861,193**
Reserves in consolidated companies	79,329	57,649
Treasury shares	(2,644)	(2,858)
Total other reserves	**837,939**	**915,984**

There is a limit on distributions that would reduce the balance of reserves of the Parent company to an amount less than the total outstanding balance of development costs, which come to €26.1 million at 30 June 2024 (€14.1 million at 31 December 2023).

Reserves Investments Canary Islands

In compliance with the requirements of Law 19/1994, and in order to be able to benefit from the tax incentives that it establishes, the Parent Company allocates to these Reserves for Canary Islands Investments (R.I.C.) part of the profits obtained by the establishment located in the Canary Islands, which is a restricted reserve since the assets of which it consists must remain within the company.

On 30 June 2024 and 31 December 2023 the balance of these reserve comes to €3,485 thousand, included under "Other Reserves of the Parent Company".

Reserves for amortized capital

In accordance with the revised text of the Spanish Capital Companies Act, these reserves may only be used subject to the same requirements as for the reduction of share capital.

On 30 June 2024 and 31 December 2023, the balance of these reserves amounts to €30,540 thousand.

Liquidity contract and treasury shares

The Parent Company has a liquidity contract with a financial intermediary, effective as from 4 March 2019, with the aim of favouring liquidity and stability of prices of the Company’s shares, within the limits established by the General Shareholders’ Meeting and by current regulations, in particular, Circular 1/2017, of 26 April, of the National Securities Market Commission (CNMV), on liquidity contracts. This contract means that, at 30 June 2024, the Parent Company holds treasury shares representing 0.09% of the share capital (0.09% on 31 December 2023) and an overall nominal value of €22.8 thousand (€23.0 thousand at 31 December 2023), which have been recognised in accordance with EU-IFRS. The average acquisition price of these shares was €9.7 per share. The treasury shares held by the Parent Company are intended to be traded on the market.

Valuation adjustments and other adjustments

On 30 June 2024 and 31 December 2023, the amount of this heading comes to -€33,205 thousand, and it corresponds to:

- Net accumulated actuarial losses due to recalculations of the valuations of the retirement benefit obligations as a result of changes in the calculation assumptions: -€20,419 thousand on 30 June 2024, and -€23,113 thousand on 31 December 2023.
- Financial assets measured at fair value through other comprehensive income: as explained in Note 12 to the consolidated financial statements for the year ending 31 December 2023, in accordance with IFRS 9, the Group recognised the impairment losses of the investee companies Suneva Medical Inc. and Dermelle LLC under this heading. On 30 June 2024 and 31 December 2023, the accumulated balance is -€10,092 thousand.

Translation differences

This heading in the accompanying condensed consolidated interim balance sheet includes the net amount of exchange differences arising on the translating the equity of companies with a functional currency other than the euro into the Group's reporting currency.

On 30 June 2024 and 31 December 2023, the breakdown of the balance of this item by companies in the condensed consolidated interim balance sheet is as follows:

	Thousands of Euros	
	30/06/2024	**31/12/2023**
Almirall Inc / Almirall LLC (USA)	49,850	41,609
Almirall Limited (UK)	(546)	(956)
Other subsidiaries	2,685	3,174
Total translation differences	**51,989**	**43,827**

The movement for the six-month period ending 30 June 2024 has been as follows:

	Thousands of Euros
Balance as at 31 December 2023	**43,827**
Variations due to exchange differences	8,162
Balance as at 30 June 2024	**51,989**

17. Deferred income

The movement and balance of this heading for the six-month period ending 30 June 2024 are as follows:

	Thousands of Euros
Balance as at 31 December 2023	**-**
Additions	5,178
Allocation to income (Note 22)	(857)
Balance as at 30 June 2024	**4,321**

The additions correspond to the difference between the nominal value and the fair value of the loans granted by the CDTI (Note 19). The allocation to income corresponds to the income accrued on the basis of the progress of each of the financed projects (mainly between 1 and 2 years), which is recorded under the heading "Other income" in the condensed consolidated interim income statement (Note 22).

18. Financial liabilities

As detailed in Note 5-i) to the consolidated financial statements for the year ending 31 December 2023, the Group classifies its financial liabilities into the following valuation categories:

- Financial liabilities measured at fair value through profit or loss: this heading includes liabilities related to derivative financial instruments, provided that it is not a financial guarantee contract and that it has not been designated as a hedging instrument.
- Financial liabilities measured at amortised cost: this heading mainly includes unsecured bonds, bank loans and revolving credit facilities. At the date of initial application, the Group's business model is to maintain this financing to pay contractual cash flows that represent only payments of principal and interest on the principal amount.

The itemisation of this heading in the condensed consolidated interim balance sheet on 30 June 2024 and 31 December 2023 is as follows:

(Thousands of euros)

	Limit	Balance drawn down (*)	Current	Non-current			
				2025/2026	2026/2027	Rest	Total
Financial liabilities at amortised cost							
Credit facilities	275,000	-	-	-	-	-	-
Loans with credit institutions	80,000	50,000	10,000	10,000	10,000	20,000	40,000
Senior unsecured bonds	300,000	297,422	-	-	297,422	-	297,422
Financial liabilities at fair value through profit or loss							
Liabilities for derivative financial instruments	N/A	-	-	-	-	-	-
Accrued interest to be paid	**N/A**	**2,309**	**2,309**	**-**	**-**	**-**	**-**
Total as at 30 June 2024	**655,000**	**349,731**	**12,309**	**10,000**	**307,422**	**20,000**	**337,422**

(*) Balance drawn down net of issuance costs

	Limit	Balance drawn down (*)	Current	Non-current			
				2025	2026	Rest	Total
Financial liabilities at amortised cost							
Credit facilities	275,000	-	-	-	-	-	-
Loans with credit institutions	80,000	55,000	10,000	10,000	10,000	25,000	45,000
Senior unsecured bonds	300,000	296,851	-	-	-	296,851	296,851
Financial liabilities at fair value through profit or loss							
Liabilities for derivative financial instruments	N/A	1,569	1,569	-	-	-	-
Accrued interest to be paid	**N/A**	**2,399**	**2,399**	**-**	**-**	**-**	**-**
Total as at 31 December 2023	**655,000**	**355,819**	**13,968**	**10,000**	**10,000**	**321,851**	**341,851**

(*) Balance drawn down net of issuance costs

Senior unsecured bonds

On 22 September 2021, the Parent Company proceeded to conclude and disburse an issuance of senior unsecured bonds for an aggregate nominal amount of €300 million, at a fixed annual interest rate of 2.125%, maturing on 22 September 2026. The bonds were placed among qualified investors by BNP Paribas and JP Morgan AG, as coordinating entities. The effective interest rate of these bonds is 2.5%.

The debt from these bonds is stated at the nominal amount (€300 million) net of issuance costs (which amounted to €5.6 million), which will be recorded over the life of the bonds at amortised cost using the effective interest method.

Debts with credit institutions

Details of debts with credit institutions as at 30 June 2024 and 31 December 2023 are as follows:

	Limit	Balance drawn down	Final maturity	Nominal interest rate	Effective interest rate
Debts with credit institutions					
Revolving credit facility	275,000	-	02/02/2028	4.88% (Euribor + Margin)	4.88%
European Investment Bank Loan	80,000	50,000	17/04/2029	1.65%	1.65%
Total as at 30 June 2024	**355,000**	**50,000**			

	Limit	Balance drawn down	Final maturity	Nominal interest rate	Effective interest rate
Debts with credit institutions					
Revolving credit facility	275,000	-	17/07/2024	5.16% (Euribor + Margin)	5.16%
European Investment Bank Loan	80,000	55,000	17/04/2029	1.65%	1.65%
Total as at 31 December 2023	**355,000**	**55,000**			

On 2 February 2024, the revolving credit facility previously signed in 2020 was novated for the same amount (€275 million), maintaining the same contractual conditions and for an initial term of 4 years (until February 2028, with the possibility of an extension of 1 additional year), for general corporate use.

On 27 March 2019, the Parent Company arranged a loan facility with the European Investment Bank (EIB) for up to €120 million to fund its research and development efforts, with the objective of providing cutting-edge innovation and differentiated therapies in the area of medical dermatology. On 17 April 2019, the first tranche of €80 million was granted, with 32 equal repayments of principal between 17 July 2021 and 17 April 2029, with the latter date being the final maturity. Due to the issue of new debt in 2021, the interest rate increased by 0.30%.

The debt contracts oblige the Parent Company to comply with a series of covenants, which at 30 June 2024 and 31 December 2023 are complied with.

Derivative financial instruments

On 10 May 2018, the Ordinary General Meeting of Shareholders arranged the completion of a swap transaction of interest rate and shares (“Equity swap”). This transaction entered into force by means of a contract dated 11 May 2018 with Banco Santander, S.A., whereby Almirall S.A. is bound to pay variable interest to the bank as compensation and Banco Santander, S.A. undertakes, as the acquirer of underlying ordinary shares of the company Almirall S.A. with a maximum nominal limit of 2.99% of the share capital (5,102,058 shares or €50 million), to hand over the dividend received for its investment in Almirall S.A. Said instrument was renewed in December 2023 for a term of 2 years.

In addition, when the fair value is less than 85% of the cost value, the Group must offset the loss by contributing cash to the bank (in this case reducing the recognised value of the derivative). Once a settlement has been made, if the fair value exceeds 110% of the last value at which a settlement occurred, then the Group will reclaim the payments made proportionately up to 100% of the initial value of the derivative (always limited to the cost of acquisition by Banco Santander). For this reason, the Group has opted to classify this asset/liability as current.

Consequently, under the heading “Assets resulting from derivative financial instruments” (in the case of unrealised gains) or “Liabilities resulting from derivative financial instruments” (in the case of unrealised losses), the fair value of the derivative has been recognised, which corresponds to the difference between the fair value of the underlying asset and the acquisition cost of the shares for Banco Santander (2,510,952 shares equivalent to €35.1 million, corresponding to 1.2% of the Parent Company’s share capital). The following table details the impacts at 30 June 2024 and at 31 December 2023:

	Thousands of euros	
	30/06/2024	**31/12/2023**
Underlying asset:		
Fair value	23,603	21,155
Acquisition cost	35,073	35,073
Capital gain / (capital loss)	**(11,470)**	**(13,918)**
Disbursements made to date	12,349	12,349
Asset / (liability) per derivative financial instrument	**879**	**(1,569)**
Profit / (Loss) for the period (Note 22)	**2,448**	**(1,544)**

Other financial debt considerations

At the date of preparation of these condensed consolidated interim financial statements, the Parent Company’s Directors consider that no breach of the aforementioned obligations (including the aforementioned series of covenants) has occurred.

For the six-month period ending 30 June 2024 and 2023, the average cost of debt was 1.6% and 1.5%, respectively. Most of the Group's debt has a fixed interest rate, which limits its exposure to interest rate risk.

The interest accrued and payable at 30 June 2024 amounts to €2,309 thousand (€2,399 thousand at 31 December 2023), and it corresponds mainly to senior unsecured bonds.

Moreover, in application of the amendment to IAS 7, below we provide a reconciliation of the cash flows arising from financing activities with the corresponding liabilities in the opening and closing statements of financial position, separating the movements that involve cash flows from those that do not.

	Balance 01.01.2024	Cash Flow	Interest paid	Interest accrued	Changes in fair value	Balance 30.06.2024
Financial liabilities at amortised cost						
Credit facilities	-	-	-	-	-	-
Loans with credit institutions	55,000	(5,000)	-	-	-	50,000
Senior unsecured bonds	296,851	-	-	571	-	297,422
Financial liabilities at fair value through profit or loss						
Liabilities for derivative financial instruments	1,569	-	-	-	(1,569)	-
Accrued interest to be paid	**2,399**	**-**	**(4,995)**	**4,905**	**-**	**2,309**
Total Financial debt	**355,819**	**(5,000)**	**(4,995)**	**5,476**	**(1,569)**	**349,731**

	Balance 01.01.2023	Cash Flow	Interest paid	Interest accrued	Changes in fair value	Balance 30.06.2023
Financial liabilities at amortised cost						
Credit facilities	-	-	-	-	-	-
Loans with credit institutions	65,000	(5,000)	-	-	-	60,000
Senior unsecured bonds	295,758	-	-	547	-	296,305
Financial liabilities at fair value through profit or loss						
Liabilities for derivative financial instruments	25	-	-	-	3,679	3,704
Accrued interest to be paid	**2,377**	**-**	**(5,244)**	**5,161**	**-**	**2,294**
Total Financial debt	**363,160**	**(5,000)**	**(5,244)**	**5,708**	**3,679**	**362,303**

19. Trade payables and Other liabilities

Trade payables

On 30 June 2024 and 31 December 2023 this heading is itemised as follows:

	Thousands of Euros	
	30/06/2024	31/12/2023
Suppliers	75,176	82,657
Trade payables	107,154	98,697
Total short-term trade payables	**182,330**	**181,354**

Other liabilities

On 30 June 2024 and 31 December 2023 this heading is itemised as follows:

	Thousands of Euros				
		Non-current			
	Current	2024/2025	2025/2026	Rest	Total
Loans linked to research	1,548	1,318	223	12,799	14,340
Debts for purchases of fixed assets	7,525	2,556	-	8,028	10,584
Remuneration to be paid	30,716	2,055	4,446	3,503	10,004
Long-term tax liabilities	-	-	-	6,698	6,698
Other debts	103	-	-	24	24
Total as at 30 June 2024	**39,892**	**5,929**	**4,669**	**31,052**	**41,650**

	Thousands of Euros				
		Non-current			
	Current	2024	2025	Rest	Total
Loans linked to research	1,004	1,096	444	5,040	6,580
Debts for purchases of fixed assets	89,256	2,494	-	7,831	10,325
Remuneration to be paid	30,150	2,579	2,093	6,428	11,100
Long-term tax liabilities	-	-	-	6,698	6,698
Other debts	93	-	-	24	24
Total as at 31 December 2023	**120,503**	**6,169**	**2,537**	**26,021**	**34,727**

There are no significant differences between the fair value of the liabilities and the recognised amount.

Research-linked loans correspond mainly to loans at subsidised interest rates and/or with grace periods, granted by the Ministry of Science and Technology to promote research. The granting of these loans is subject to compliance with carrying out certain investments and expenses during the years for which they are granted, and the loans mature between 2023 and 2041. In the first half of 2024, various loans were granted for a nominal value of €18.8 million. The difference between the nominal value and the fair value of said loans is recorded under deferred income (Note 17).

Debts for purchases of fixed assets refer basically to disbursements pending for the acquisition of goods, products and marketing licenses contracted in the fiscal year and prior years, among them the milestones described in Note 9.

The current balance of “Remuneration to be paid” mainly includes balances to be paid to employees corresponding to the accrued portions of bonus payments, as well as the bonuses for achieving the Group’s targets. The non-current balance mainly includes the long-term remuneration plans described in Note 5-s) of the notes to the consolidated financial statements for the year ended 31 December 2023. In this respect, it is worth mentioning that at the General Shareholders’ Meeting on 10 May 2024, a new long-term remuneration plan called the “Performance Shares Plan” was approved, which has the following differences compared to the SEUS plans granted until 31 December 2023:

- The Plan is exceptional and multi-year in nature, running from 1 January of year 1 to 31 December of year 3, with the corresponding incentive paid in March of year 4. The first cycle of the plan begins on 1 January 2024.
- The allocated Performance Shares will be settled as follows: 40% in cash based on the market value of the Almirall, S.A. share on the settlement date, and 60% in Almirall, S.A. shares, where each Performance Share is equivalent to one share.

Finally, as a result of applying IFRIC 23, "Uncertainty regarding income tax treatment" (Note 5-q) to the consolidated financial statements for the year ending 31 December 2023, at 30 June 2024 an amount of €6,698 thousand has been classified as "Long-term tax liabilities” (€6,698 thousand at 31 December 2023).

20. Retirement benefit obligations

The retirement benefit obligations are related to the subsidiaries Almirall Hermal, GmbH, Almirall, AG and Polichem, S.A. and are related to unfunded plans (there are no assets assigned to these plans).

	Thousands of Euros
Balance as at 31 December 2023	**60,481**
Actuarial losses / (gains)	(3,742)
Interest cost	1,248
Benefits paid	(1,353)
Balance as at 30 June 2024	**56,634**

Compared to 31 December 2023, the main change in liabilities is due to the increase in the interest rate used in the actuarial calculation assumptions.

21. Provisions

The composition of and movement in this heading of the condensed consolidated interim balance sheet during the six-month period ending 30 June 2024 was as follows:

	Thousands of Euros
Balance as at 31 December 2023	**13,926**
Additions and provisions	105
Reversal	-
Balance as at 30 June 2024	**14,031**

It refers mainly to the provision for long-term remuneration (see Note 5-s to the consolidated financial statements for the year ending 31 December 2023) and to the Group's estimate of the disbursements that it would have to make in the future to meet other liabilities arising from the nature of its business. There have been no significant variations with respect to 31 December 2023.

22. Income and expenses

Net turnover

The tables below detail the net turnover for the six-month periods ending on 30 June 2024 and 2023, separated by items and segments:

	Thousands of Euros	
	2024 Period	**2023 Period**
Sales of products	491,029	446,983
Income from granting licenses	6,189	19,077
Net turnover	**497,218**	**466,060**

	Thousands of Euros	
	2024 Period	**2023 Period**
Marketing through own network	434,354	407,205
Marketing through licensees	48,690	48,181
Manufacturing for third parties and intermediation	14,174	10,674
Net turnover	**497,218**	**466,060**

The net turnover amount by geographic area, together with details of the main countries in which it is obtained, is shown below:

	Thousands of Euros	
	2024 Period	2023 Period
Spain	159,254	160,365
Europe and Middle East	283,829	250,054
America, Asia and Africa	54,135	55,641
Net turnover	**497,218**	**466,060**

	Thousands of Euros	
	2024 Period	2023 Period
Spain	159,254	160,365
Germany	132,742	107,864
Italy	45,835	38,664
United States	27,974	29,230
France	19,186	21,867
United Kingdom	13,379	14,682
Other countries	98,848	93,388
Net turnover	**497,218**	**466,060**

Finally, the contribution from the main therapeutic areas of the various products sold by the Group is detailed:

	Thousands of Euros	
	2024 Period	2023 Period
Dermatology and others	268,793	231,318
Gastrointestinal and metabolism	47,690	64,379
Respiratory	57,988	55,582
Cardiovascular	44,402	42,511
Central nervous system	41,522	36,295
Musculoskeletal	17,541	14,652
Other therapeutic specialities	19,282	21,323
Net turnover	**497,218**	**466,060**

Other income

The following table provides an itemisation of the composition of this heading for the six-month periods ending 30 June 2024 and 2023:

	Thousands of Euros	
	2024 Period	2023 Period
Income due to agreement with Covis (Note 12)	518	704
Allocation of deferred income (Note 17)	857	-
Others	1,483	469
Total Other income	**2,858**	**1,173**

Supplies

The itemisation of this heading for the six-month periods ending 30 June 2024 and 2023 is as follows:

	Thousands of Euros	
	2024 Period	2023 Period
Purchases	118,753	128,569
Change in stocks of finished or semi-finished products	(4,214)	(10,034)
Change in stocks of raw materials and goods	4,789	(3,388)
Total Procurement	**119,328**	**115,147**

Staff

The itemisation of staff costs for the six-month periods ending 30 June 2024 and 2023 is as follows:

	Thousands of Euros	
	2024 Period	**2023 Period**
Payroll and salaries	91,470	82,327
Social security payable by the company	17,237	15,397
Severance payments	1,522	1,525
Other welfare expenses	7,881	7,760
Total	**118,110**	**107,009**

The average number of employees of the Group for the six-month periods ending 30 June 2024 and 2023, by professional category and gender, is as follows:

	2024 Period			**2023 Period**		
	Men	**Women**	**Total**	**Men**	**Women**	**Total**
Directors	1	-	1	1	-	1
Executives	63	40	103	66	40	106
Managers	104	92	196	100	91	191
Technical staff	462	646	1,108	452	591	1,043
Administrative staff	266	276	542	257	275	532
Others	-	2	2	-	2	2
Total	**896**	**1,056**	**1,952**	**876**	**999**	**1,875**

On 30 June 2024 and 31 December 2023, the make-up of the staff was as follows:

	30 June 2024			**31/12/2023**		
	Men	**Women**	**Total**	**Men**	**Women**	**Total**
Directors	1	-	1	1	-	1
Executives	64	40	104	65	40	105
Managers	106	95	201	100	90	190
Technical staff	474	677	1,151	447	589	1,036
Administrative staff	265	272	537	264	278	542
Others	-	2	2	-	2	2
Total	**910**	**1,086**	**1,996**	**877**	**999**	**1,876**

In addition, at 30 June 2024 the number of non-employee directors was 9, of whom 4 were women and 5 were men (at 31 December 2023, there were 8, of whom 3 were women and 5 were men).

The number of Group employees at 30 June 2024 with a functional limitation of equal to or greater than thirty-three per cent is 41 people (36 people on 31 December 2023).

Other operating expenses

The itemisation of this heading for the six-month periods ending 30 June 2024 and 2023 is as follows:

	Thousands of Euros	
	2024 Period	2023 Period
R&D activities	38,057	29,529
Leases and fees	25,918	19,644
Repairs and maintenance	11,103	11,903
Independent professional services	13,563	11,975
Transport	7,652	7,006
Insurance premiums	1,688	1,596
Bank services and similar	378	309
Congresses and other promotional activities	46,527	43,664
Supplies	2,487	3,302
Other services	21,057	15,101
Other taxes	847	2,249
Total	**169,277**	**146,278**

The heading of leases and royalties includes royalties linked mainly to several of the licence agreements described in Note 9. The amounts corresponding to the 2024 and 2023 periods reached €18.5 million and €13.2 million, respectively. The increase is mainly explained by the growth in sales of products marketed under the Ilumetri, Wynzora and Ebglyss brands.

Net gains (losses) on disposal of assets

The details of this heading for the six-month periods ending 30 June 2024 and 2023 are as follows:

	Thousands of Euros			
	2024 Period		2023 Period	
	Gains	Losses	Gains	Losses
For disposal or retirement of intangible assets	-	(2,426)	1	-
For disposal or retirement of property, plant and equipment	-	(745)	-	(1)
	-	**(3,171)**	**1**	**(1)**
Net gains (losses) on disposal of assets	**(3,171)**		**-**	

The losses recorded in the 2024 period relate to the termination of the development contract and the discontinuation of a product (both mentioned in Note 9) and to the sale of land mentioned in Note 11.

Financial result

The details of the Financial result for the six-month periods ending 30 June 2024 and 2023 are as follows:

	Thousands of Euros			
	2024 Period		2023 Period	
	Income	Expenses	Income	Expenses
Bond issuance costs (Note 18)	-	(3,720)	-	(3,720)
Financial and similar income / (expenses)	3,749	(4,317)	1,085	(3,668)
Change in fair value of financial instruments (Note 18)	2,448	-	-	(3,679)
Exchange rate differences	-	(598)	-	(771)
	6,197	**(8,635)**	**1,085**	**(11,838)**
Financial result	**(2,438)**		**(10,753)**	

The breakdown of “Other finance income/(expenses) and similar” includes financial expenses derived from bank loans, as well as the impact of the financial restatement of liabilities carried at amortised cost and the financial cost of the pension payments, with the exception of the financial cost of the senior unsecured bonds (as described in Note 18), which is included in the breakdown of "Bond issuance costs" (€3.7 million in both periods).

In addition, with the rise in interest rates in 2023, the Group earned interest income of €3.7 million, mostly from investments in deposits made during the period, although they all had matured at 30 June 2024. Given that the rate hike started in the second half of 2023, revenues increased significantly compared to the same period in 2023.

The result recorded under the heading "Change in fair value of financial instruments" corresponds to the change in the fair value of the equity swap (as explained in Note 18), with a profit of €2.4 million in FY 2024 (a loss of €3.7 million in FY 2023).

23. Tax situation

Balances held with the Public Administration

The balances receivable from and payable to the Public Administrations as at 30 June 2024 and 31 December 2023 are as follows:

	Thousands of Euros	
	30/06/2024	**31/12/2023**
Public Treasury (Hacienda) VAT owed	6,169	8,302
Public Treasury (Hacienda) Corporate Income Tax owed	13,816	7,223
Other debts	10	11
Total debtor balance	**19,995**	**15,536**
Public Treasury (Hacienda) VAT paid	3,401	3,505
Personal income tax	6,900	6,594
Social Security Agencies creditors	3,721	3,536
Public Treasury (Hacienda) Corporate Income Tax creditor	18,929	15,409
Total credit balances	**32,951**	**29,044**

Fiscal years subject to tax inspection

On 15 February 2024, the Tax Agency notified Ranke Química, S.A. of the commencement of the inspection and investigation of the excise tax on alcohol for the year 2021. At the date of preparation of these condensed consolidated interim financial statements, this inspection is still in progress.

Consequently, the Parent Company and the companies forming part of the Spanish tax group are currently being audited for fiscal years 2019 to 2022 regarding Corporate Income Tax, and for fiscal years 2020 to 2023 for all other applicable taxes.

During the financial year 2022, the following inspection procedure was communicated in respect of the Group's following foreign company: Almirall Inc. and investee companies (United States). This inspection has to do with Corporate Income Tax for 2015, 2016, 2018 and 2020. At the date of preparation of these condensed consolidated interim financial statements, this inspection is still in progress.

During the financial year 2023, the inspection procedure was notified regarding the following foreign companies of the group, whose situation is summarised below:

- Almirall Hermal GmbH (Germany), in respect of the financial years 2018, 2019, 2020, and 2021, relating to Corporate Income Tax, Value Added Tax, as well as Withholdings and income on account for Personal Income Tax.
- Polichem SA (Luxembourg), in respect of the fiscal years 2019, 2020 and 2021, relating to Value Added Tax. This inspection was completed in 2024, with no significant aspect arising.
- Polichem SA (Switzerland), for the fiscal years 2020 and 2021, concerning the Cantonal Tax of Ticino in Switzerland. This inspection was completed in 2024, with no significant aspect arising.

During the six-month period ending 30 June 2024, no inspections additional to those mentioned above have been initiated.

All other foreign companies of the Group are currently open to audits regarding the applicable taxes for the corresponding years in each of the local legislations.

The administrators do not expect any liabilities to arise as a result of the above inspections that would materially affect these condensed consolidated interim financial statements as at 30 June 2024.

In general, due to the different ways in which the tax regulations may be interpreted, the results of the inspections that are being carried out, or that may be carried out in the future by the tax authorities, for the years subject to verification, may give rise to tax liabilities of an amount that cannot be objectively quantified at present. In the opinion of the Parent Company's administrators, however, the possibility of significant liabilities arising in this respect, in addition to those recognised, is remote.

Deferred taxes

In relation to the recoverability of deferred tax assets (mainly originating in the Spanish tax group), there has been no significant change in the estimate of future taxable profits made in the recoverability analysis described in Note 22 of the notes to the consolidated financial statements for the year ending 31 December 2023.

During the six months ended 30 June 2024, there have been no significant movements in deferred tax assets and liabilities.

Corporate income tax expense

The corporate income tax expense is recognised on the basis of the best estimate for the period, which does not differ significantly from the weighted average tax rate expected for the annual accounting period.

Global minimum complementary tax

The Group is subject to the global minimum complementary tax under Pillar Two tax legislation, after the Council of Ministers approved, on 19 December 2023, the draft law transposing the European directive to guarantee this global minimum taxation of 15% in Spain.

As at 30 June 2024, the Group is assessing those tax jurisdictions in which a complementary tax could be recognised, with Spain being the only significant one in the event of facing any payment, also considering the operations of its majority shareholder (ultimate parent for the purposes of this regulation), which is also located in this territory and where the statutory rate is 25%.

24. Business segments

Segmentation criteria

The segmentation criteria used in the preparation of the consolidated interim financial information of the Almirall Group are consistent with those used in the preparation of the consolidated financial statements for the year ending 31 December 2023. Note 23 of these financial statements provides details on the basis and methodology used to prepare the financial information by segments, where there are no intersegment revenues.

(Thousands of euros)

Segment reporting by business

Segmented income statement for the six months ending 30 June 2024:

	Commercial areas			Other areas			
	Own network (Europe)	Own network (USA)	Licensees	R & D	Corporate services and manufacturing	Reclassi-fications	Total
Net turnover	406,380	27,974	48,690	-	14,174	-	497,218
Other Income	-		-	-	2,858	-	2,858
Operating income	**406,380**	**27,974**	**48,690**	**-**	**17,032**	**-**	**500,076**
Work carried out on fixed assets	-	-	-	12,396	-	-	12,396
Supplies	(110,977)	(5,551)	(21,472)	(731)	(17,990)	37,393	(119,328)
Staff costs	(42,124)	(7,869)	(748)	(16,217)	(31,803)	(19,349)	(118,110)
Depreciation	(31,972)	(13,121)	(4,964)	(4,188)	(8,787)	(5,569)	(68,601)
Net change in valuation adjustments	(598)	585	(9)	-	(1,253)	-	(1,275)
Other operating expenses	(70,175)	(13,178)	(3,185)	(48,063)	(22,201)	(12,475)	(169,277)
Net gains (losses) on disposal of assets	-	-	-	-	(3,171)	-	(3,171)
Operating profit	**150,534**	**(11,160)**	**18,312**	**(56,803)**	**(68,173)**	**-**	**32,710**
Financial income	-	-	-	-	3,749	-	3,749
Financial expenses	-	-	-	-	(8,037)	-	(8,037)
Exchange rate differences	-	-	-	-	(598)	-	(598)
Valuation gains on financial instruments	-	-	-	-	2,448	-	2,448
Earnings before tax	**150,534**	**(11,160)**	**18,312**	**(56,803)**	**(70,611)**	**-**	**30,272**
Corporate income tax	-	-	-	-	(14,882)	-	(14,882)
Net profit for the year attributable to the Parent Company	**150,534**	**(11,160)**	**18,312**	**(56,803)**	**(85,493)**	**-**	**15,390**

(Thousands of euros)

Segmented income statement for the six months ending 30 June 2023:

	Commercial areas			Other areas			Total
	Own network (Europe)	**Own network (USA)**	**Licensees**	**R & D**	**Corporate services and manufacturing**	**Reclassi-fications**	**Total**
Net turnover	363,334	29,229	47,822	-	25,675	-	466,060
Other Income	-	-	-	112	1,061	-	1,173
Operating income	**363,334**	**29,229**	**47,822**	**112**	**26,736**	**-**	**467,233**
Work carried out on fixed assets	-	-	-	3,217	-	-	3,217
Supplies	(102,427)	(7,230)	(22,188)	(881)	(16,741)	34,320	(115,147)
Staff costs	(38,664)	(10,500)	(569)	(13,806)	(25,842)	(17,628)	(107,009)
Depreciation	(19,815)	(22,820)	(4,998)	(2,519)	(7,556)	(5,122)	(62,830)
Net change in valuation adjustments	-	(252)	-	-	(58)	-	(310)
Other operating expenses	(58,482)	(16,802)	(2,665)	(38,532)	(18,227)	(11,570)	(146,278)
Operating profit	**143,946**	**(28,375)**	**17,402**	**(52,409)**	**(41,688)**	**-**	**38,876**
Financial income	-	-	-	-	1,085	-	1,085
Financial expenses	-	-	-	-	(7,388)	-	(7,388)
Exchange rate differences	-	-	-	-	(771)	-	(771)
Valuation gains on financial instruments	-	-	-	-	(3,679)	-	(3,679)
Earnings before tax	**143,946**	**(28,375)**	**17,402**	**(52,409)**	**(52,441)**	**-**	**28,123**
Corporate income tax	-	-	-	-	(16,108)	-	(16,108)
Net profit for the year attributable to the Parent Company	**143,946**	**(28,375)**	**17,402**	**(52,409)**	**(68,549)**	**-**	**12,015**

Assets of the condensed consolidated interim balance sheet on 30 June 2024 segmented:

	Commercial areas			Other areas		
	Own network (Europe)	**Own network (USA)**	**Licensees**	**R & D**	**Corporate services and manufacturing**	**Total**
Goodwill	270,550	-	45,416	-	-	315,966
Intangible assets	433,064	212,880	145,785	118,817	17,521	928,067
Right-of-use assets	6,235	2,602	86	-	35,703	44,626
Property, plant and equipment	1,166	6,124	16	26,369	107,371	141,046
Financial assets	-	-	-	-	19,603	19,603
Deferred tax assets	1,954	5,154	5,740	-	165,993	178,841
NON-CURRENT ASSETS	**712,969**	**226,760**	**197,043**	**145,186**	**346,191**	**1,628,149**
Stocks	114,617	6,054	11,097	-	35,112	166,880
Trade and other receivables	83,679	29,476	27,152	-	17,843	158,150
Current tax assets	-	5,190	-	-	14,805	19,995
Other current assets	-	1,889	-	-	15,448	17,337
Current financial investments	-	-	-	-	1,468	1,468
Cash and cash equivalents	-	-	-	-	329,407	329,407
CURRENT ASSETS	**198,296**	**42,609**	**38,249**	**-**	**414,083**	**693,237**
TOTAL ASSETS	**911,265**	**269,369**	**235,292**	**145,186**	**760,274**	**2,321,386**

Assets of the consolidated balance sheet on 31 December 2023 segmented:

	Commercial areas			Other areas		
	Own network (Europe)	**Own network (USA)**	**Licensees**	**R & D**	**Corporate services and manufacturing**	**Total**
Goodwill	270,550	-	45,416	-	-	315,966
Intangible assets	489,973	210,162	153,894	81,320	16,066	951,415
Right-of-use assets	11,386	-	101	-	31,529	43,016
Property, plant and equipment	577	5,552	19	26,242	108,897	141,287
Financial assets	-	-	-	-	22,878	22,878
Deferred tax assets	1,985	4,993	5,740	-	169,043	181,761
NON-CURRENT ASSETS	**774,471**	**220,707**	**205,170**	**107,562**	**348,413**	**1,656,323**
Stocks	114,116	9,886	11,595	-	31,931	167,528
Trade and other receivables	69,646	26,199	17,767	-	17,886	131,498
Current tax assets	-	4,846	-	-	10,690	15,536
Other current assets	-	3,488	-	-	12,522	16,010
Current financial investments	-	-	-	-	136	136
Cash and cash equivalents	-	-	-	-	387,954	387,954
CURRENT ASSETS	**183,762**	**44,419**	**29,362**	**-**	**461,119**	**718,662**
TOTAL ASSETS	**958,233**	**265,126**	**234,532**	**107,562**	**809,532**	**2,374,985**

Additions to non-current assets by segment during the six-month periods ending:

	Thousands of euros	
	30/06/2024	**30/06/2023**
Own network (Europe)	-	39,762
Own network (USA)	-	35
R & D	27,041	6,127
Corporate services and manufacturing	16,594	11,941
Total additions	**43,635**	**57,865**

The Group does not itemise information about relevant clients by segments, as none of them individually represents more than 10% of the Group's net turnover.

25. Dividends paid by the Parent Company

The dividends paid by the Parent Company during the first six-month periods ending 30 June 2024 and 2023 are shown below:

	First Half Year 2024			First Half Year 2023		
	% of nominal	**Euros per share**	**Amount (Thousands of Euros)**	**% of nominal**	**Euros per share**	**Amount (Thousands of Euros)**
Ordinary shares	158%	0.19	39,785	158%	0.19	34,488
Total Dividends paid	**158%**	**0.19**	**39,785**	**158%**	**0.19**	**34,488**
Dividends charged to income statement	158%	0.19	39,785	158%	0.19	34,488

The 2024 and 2023 dividend payments have been implemented as a flexible dividend in which shareholders have been offered the choice between receiving newly issued Parent Company shares or the cash amount equivalent to the dividend.

In 2024, the cash payment was chosen by 8.5% of the rights (which meant a disbursement of €3.3 million), and the remaining 91.5% opted to receive new shares, each at par value, which were issued as a capital increase (Note 16).

In 2023, the cash payment was chosen by 7.8% of the rights (which meant a disbursement of €2.6 million), while the remaining 92.2% opted to receive new shares, each at par value, which were issued as a capital increase (Note 16).

When a dividend is approved, which may be settled in cash or through the issue of fully paid-up shares at the investor's option, i.e., remuneration with shares for a specific value, the corresponding liability must be recognised with a charge to reserves equivalent to the fair value of the rights to be allotted shares at no charge. If the investor opts to subscribe for fully paid-up shares, then the corresponding capital increase will be recognised. If the investor elects to collect the dividend, then the liability will be derecognised with a credit to the cash paid.

26. Basic earnings / (loss) per share

Basic earnings per share is calculated by dividing the net profit for the period that can be attributed to the Parent Company by the weighted average number of ordinary shares outstanding during the period, excluding the average number of treasury shares held for the entire period.

Diluted earnings per share are calculated by dividing net profit for the period attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, adjusted by the weighted average number of ordinary shares that would be issued if all the potential ordinary shares were converted into ordinary shares of the Parent Company. The calculation takes into account the consolidated profit for the year attributable to the Parent Company, excluding the expense incurred by financial instruments convertible into shares, net of the related tax effect, if any. At the end of the six-month periods ending 30 June 2024 and 2023, there were no financial instruments with dilutive effects.

Accordingly:

	2024 Period	**2023 Period**
Net result of the year (thousands of euros)	15,390	12,015
No. of weighted average ordinary shares available (*)	209,797	209,797
No. of weighted average diluted shares (**)	209,797	209,797
Basic earnings per share (euros)	**0.07**	**0.06**
Diluted earnings per share (euros)	**0.07**	**0.06**

(*) Number of issued shares, less treasury shares
(**) Average number of ordinary shares available.

As described in Note 16, during the six-month period ending 30 June 2024, a total of 4,074,994 new shares of the Parent Company were created in the capital increase on 12 June 2024.

In accordance with the provisions of IAS 33, this capital increase has been taken into account in the earnings per share corresponding to the first semester of 2023, whose value decreased €0.06 per share (€0.07 per share according to what was published in the condensed consolidated interim financial statements for the six-month period ending 30 June 2023).

27. Commitments, contingent liabilities and contingent assets

a) Commitments

As a result of the research and development activities carried out by the Group, at 30 June 2024 and at 31 December 2023, firm agreements existed for the performance of these activities for the amount of €72.0 and €67.1 million, respectively, to be paid in future periods.

All other commitments remain as detailed in the notes to the consolidated financial statements for the year ending at 31 December 2023, with no significant changes.

b) Contingent liabilities

At the date of preparation of these condensed consolidated interim financial statements, there are no contingent liabilities that could involve significant cash outflows, except for those mentioned in Note 9, related to contingent payments for the acquisition of intangible assets.

c) Contingent assets

At the date of preparation of these condensed consolidated interim financial statements, there are no contingent assets that could give rise to significant cash inflows.

28. Transactions with related parties

Transactions between the Parent Company and its subsidiaries have been eliminated during consolidation and are not itemised in this note.

Balances and transactions with other related parties

During the interim six-month periods ending 30 June 2024 and 2023, Group companies have carried out the following transactions with related parties and have recorded the following balances as at 30 June 2024 and 31 December 2023:

Company	Related party	Concept	Period	Thousands of Euros		
				Transactions	Balances - Debtor / (Creditor) (*)	
				Transactions - Income/(Expenses)	Commercial	Lease liabilities
Almirall, S.A.	Sinkasen, S.L.U.	Leases	2024	(1,647)	-	(29,251)
			2023	(1,592)	-	(30,898)
Almirall, S.A.	Sinkasen, S.L.U.	Re-invoicing works	2024	19	10	
			2023	-	38	-

(*) Balances are at 30 June 2024 and 31 December 2023

The Group leases its headquarters from Sinkasen S.L.U., a related entity whose sole shareholder is Grupo Corporativo Landon, S.L. The lease was renewed in January 2023 for a minimum of ten years, until 31 December 2032.

Transactions with related parties are carried out at market price.

29. Remuneration of the Board of Directors and Senior Management

The amount accrued during the six-month periods ending 30 June 2024 and 2023 by the current and former members of the Parent Company's Board of Directors for all remuneration items (salaries, bonuses, allowances, remuneration in kind, life insurance, compensations, incentive schemes and social security contributions) amounted to €1,426 thousand and €940 thousand, respectively. There are life insurance policies accrued for an amount of €1,000 in the six-month period ending 30 June 2024 (€7,000 in the same period of 2023).

During the six-month period ending on 30 June 2024, third-party liability insurance premiums amounting to €119 thousand (€130 thousand in the same period of 2023) were accrued to cover possible damages caused by members of the Board of Directors and Senior Management in the performance of their duties.

In addition, the remuneration accrued, paid and unpaid, by the Parent Company's Board of Directors due to multi-year incentive and loyalty schemes and the SEUS Plan (see Note 5-s to the consolidated financial statements for the financial year ending at 31 December 2023) amounted to €422 thousand in the six-month period ending 30 June 2024 (there was none for the same period in 2023). The balance of the provision for these plans totals €1,351 thousand at 30 June 2024 (€861 thousand at 31 December 2023).

There are no other pension commitments contracted with the current and former members of the Parent Company's Board of Directors as at 30 June 2024 and 31 December 2023.

The Group has included the members of the Management Committee as senior management for the purposes of the consolidated financial statements, as long as they are not on the Board of Directors.

The amount accrued during the six-month periods ending on 30 June 2024 and 2023 by senior managers who are not members of the Parent Company's Board of Directors, for all remuneration items (salaries, bonuses, allowances, remuneration in kind, compensations, incentive schemes and social security contributions), came to €3,394 thousand and €4,050 thousand, respectively.

In addition, accrued remuneration, both paid and unpaid, for the Group's senior management under the multi-year incentive and loyalty schemes and the SEUS Plan totalled €825 thousand and €657 thousand in the six-month periods ending on 30 June 2024 and 2023, respectively. The balance of the provision for these plans totals €4,182 thousand at 30 June 2024 (€4,283 thousand at 31 December 2023).

There are no other pension commitments to the Senior Managers as at 30 June 2024 and 31 December 2023.

The members of the Board of Directors and Senior Management of the Group have not received any shares or share options during the six-month period ending 30 June 2024, nor have they exercised any options or have any options outstanding, nor have they been granted any advances or loans.

30. Events after closing

No significant events have occurred subsequent to the end of the reporting period as at the date of preparation of these condensed consolidated interim financial statements.

Almirall, S.A. and Subsidiaries
(Almirall Group)

Consolidated interim management report
(Six-month period ending 30 June 2024)

(Translation of a report originally issued in Spanish.
In the event of discrepancy, the Spanish language version prevails)

TABLE OF CONTENTS

1. Summary of the first half-year

The six-month period ending 30 June 2024 was characterised by an increase in net turnover, mainly due to the performance of the Group's dermatology portfolio in Europe. Growth is mainly being led by products marketed under the brand names Ilumetri (for treating moderate to severe plaque psoriasis), Wynzora (for treating mild to moderate psoriasis) and Ebglyss (launched in December 2023 in Germany and for treating moderate to severe atopic dermatitis). Additional launches of Ebglyss are expected in the second half of 2024 and also throughout 2025. The Spanish market is also growing thanks to products acquired throughout 2023 (Physiorelax in February and Prometax in August), which offset the erosion in sales of products marketed under the Efficib and Tesavel brands, affected by the competition from generics since August 2022.

From a macroeconomic and geopolitical point of view, the first half of 2024 has been marked by the European Central Bank's control of inflation, whereby the official interest rate has been kept high in those first six months, with a drop of 0.25% in mid-June 2024. In addition, it is important to mention that neither the conflict between Russia and Ukraine nor the recent conflict in the Middle East have had either a direct or a significant impact in the first six months of 2024.

From the point of view of R&D activities, there has been no relevant regulatory event, although two development agreements have been signed (with Novo Nordisk and Eloxx Pharmaceuticals), as explained in the following sections.

The dividend proposed by the Board of Directors on 16 February 2024 was approved at the General Meeting of Shareholders held on 10 May 2024. The payment of the dividend has been implemented as a flexible dividend in which shareholders have been offered the choice between receiving newly issued Parent Company shares or the cash amount equivalent to the dividend. The cash payment was chosen by 8.5% of the rights holders (which entailed a disbursement of 3.3 million euros), while the remaining 91.5% opted to receive new shares at the unit par value, which were issued as a capital increase. On 12 June 2024, a total of 4,074,994 new shares of the Parent Company from this flexible dividend were admitted to trading on the Barcelona, Madrid, Bilbao and Valencia stock exchanges

From a liquidity standpoint, the Group ended the semester with a cash position that amounted to €279.4 million (€388.0 million at 31 December 2023). This evolution is explained by:

- A robust cash flow from operating activities (+€66.3 million), in line with the operating profit but partially offset by interim corporate income tax payments (mainly in Germany and Switzerland) and a certain increase in working capital, although this has improved significantly with respect to the same period of 2023.
- Net payments from investment activities (-€158.2 million) resulting mainly from various licence payments accrued at the end of 2023 (€75 million), from the €50 million investment in short-term deposits, from the agreement signed with Eloxx Pharmaceuticals in 2024 and from investments in the Group's production facilities, partially offset by proceeds from the agreement with Covis Pharma GmbH and the interest from financial investments.
- Net payments from financing activities (-€16.6 million) due to interest payments on debt, quarterly repayments of the loan with the European Investment Bank, the dividend payment and financial lease payments.

2. Corporate Development

During the six-month period ending on 30 June 2024, the corporate development agreements and significant events listed below took place:

- On 16 February 2024, an agreement was signed with Novo Nordisk for the rights to NN-8828 for the use thereof in various fields, including immune-mediated inflammatory skin diseases. NN-8828 is an IL-21 blocker that inhibits IL-21-induced pathophysiological functions in several immunomodulatory diseases.
- On 11 March 2024, an agreement was signed with Eloxx Pharmaceuticals Inc. for the rights to ZKN-013, including its use in orphan dermatological diseases. ZKN-013 is a potentially promising oral drug for reading nonsense mutations, which allows host cells to produce functional proteins that counteract the root cause of these rare dermatological diseases and potentially others.
- On 10 June 2024, it was announced that the US Food and Drug Administration (FDA) had approved the Supplemental New Drug Application (sNDA), which involves extension of the treatment area to 100 cm^2 of Klisyri (tirbanibulin), a topical treatment for actinic keratosis (AK) of the face or scalp, which is applied once daily for five days. This new approval will modify the previous dosing of Klisyri for treatment, from a surface area of up to 25 cm^2 to a surface area of up to 100 cm^2, thereby allowing physicians to treat a

larger surface area on the face or scalp. This approval has been backed by an open-label Phase III safety study with over 100 patients in the United States.

3. Evolution of the main figures of the condensed consolidated interim income statement

- Operating income totalled €500.10 million (+7.0%) due to:
  - Net turnover amounted to €497.2 million, showing an increase of 6.7% thanks to the growth in dermatological products in Europe (led by Ilumetri, Ebglyss and Wynzora), partially offset by lower income from granting licences (there were two one-off agreements in the first semester of 2023).
  - Other income amounted to €2.9 million, increasing thanks to income derived from grants.
- R&D expenses in the first half of the year amounted to €56.8 million (+8.2% compared to the same period of 2023) due to the developments associated with the agreements signed at the end of 2023 and the beginning of 2024, together with the development of IL-2muFc, which has initiated Phase I, and Anti-IL-1RAP mAb, which is in Phase I.
- Staff costs increased due to the new-hires during the period, together with the salary increase of Spanish companies as a result of applying the salary review clause for the period from 2021 to 2023, as established by the collective bargaining agreement of the chemical sector in force for those years.
- Operating expenses increased as a result of the commercial roll-out of Ebglyss (for which successive launches are expected in several territories in 2024 and 2025) and of Wynzora.
- Depreciation and amortisation amounted to €68.6 million (+9.2%), increased by the start of the amortisation associated with the acquired rights of Ebglyss, partially offset by the reduction derived from the impairments made in 2023 on the rights of Seysara (an acne product marketed in the United States).
- The net financial result improved compared to the same period of 2023 as a result of the interest generated by deposits and current accounts (in 2023 they began being remunerated as from the second semester) and the positive valuation of the derivative linked to the Equity swap (due to the increase in the share price).
- For the reasons indicated above, the after-tax result amounts to a profit of €15.4 million (+28.1% compared to the same period in 2023).

4. Consolidated condensed interim balance sheet. Financial position

The main changes in the consolidated condensed interim balance sheet at 30 June 2024 compared to 31 December 2023 are described below:

- Intangible assets decreased mainly as a result of amortisation, partially offset by additions in the period and the positive effect of the US dollar on assets linked to the US business.
- Trade receivables have increased mainly due to the increase in turnover and the recognition of the right to collect various loans granted by the Spanish Ministry of Science and Technology to finance R&D activities.
- The cash position at the end of 30 June 2024 amounts to €329.4 million. The decrease is mainly due to various licence agreement milestone payments that were due at the end of 2023 but have been paid in 2024 (approx. €75 million). At 30 June 2024, this figure includes 50 million in deposits with a maturity of less than 3 months.
- Financial debt has decreased as a result of quarterly repayments of the loan from the European Investment Bank.
- Other current liabilities have decreased as a result of the milestone payments mentioned above.

5. Financial risk management and use of hedging instruments

Interest rate risk

As of 30 June 2024, most of the Group's debt is at a fixed rate, which minimises the risk of a possible increase in interest rates. As described in Note 18 of the explanatory notes, the main debt instruments are as follows:

- On 27 March 2019, the Parent Company arranged a loan facility with the European Investment Bank (EIB) for up to €120 million to fund its research and development efforts, with the objective of providing cutting-edge innovation and differentiated therapies in the area of medical dermatology. The first tranche of €80 million was granted on 17 April 2019, at a fixed interest rate of 1.351%, with 32 equal repayments of principal between 17 July 2021 and 17 April 2029, with the latter date being the final maturity. Due to the issue of new debt, the interest rate increased by 0.30%, and therefore the interest rate is 1.651%.

- On 22 September 2021, the Parent Company proceeded to conclude and disburse an issuance of senior unsecured bonds for an aggregate nominal amount of €300 million, at a fixed annual interest rate of 2.125%, maturing on 22 September 2026.
- On 2 February 2024, the credit facility previously signed in 2020 was novated for the same amount (€275 million), maintaining the same contractual conditions and for an initial term of 4 years (until February 2028, with the possibility of an extension of 1 additional year), for general corporate use. This is the only instrument with a variable interest rate, but given that the balance drawn down in this period was zero, the impact on the income statement is not significant.

Exchange rate risk

The Group, which operates mainly in US dollars, is exposed to exchange rate risk in certain transactions arising from its business activities, including receivables from sales of finished product, receivables from the transaction with Covis Pharma GmbH, payments under various licensing and development agreements (e.g. Lilly and Sun Pharma), expenses related to clinical trials and due to raw material purchases and royalties.

The Group performs a quarterly analysis of forecasts of collections and payments in foreign currency, as well as of the evolution and trend thereof, in order to plan and ensure the availability of foreign currency to meet significant payments (usually arising from milestones for licensing agreements or product acquisitions and/or new licensing transactions).

In addition, the Group maintains accounts in US dollars and pounds sterling to avoid the need for constant translation between currencies.

Finally, the Group has a hedging policy that determines when a hedging instrument should be used, such as futures and options or forward contracts. At 30 June 2024, the Group has not contracted any instrument of this type.

Liquidity risk

The Group manages liquidity risk prudently, maintaining sufficient cash and marketable securities, as well as arranging committed credit facilities for an amount sufficient to support expected needs. Cash requirements are determined using two forecasting tools with different time horizons:

- A monthly cash budget is established for one year, based on the forecast financial statements for the current year, with deviations from the forecast analysed on a monthly basis.
- Medium- and long-term liquidity planning and management is based on the Group's Strategic Plan, which covers a five-year time horizon.

Cash surpluses in euros are invested in highly liquid deposits with maturities of generally less than six months. Cash surpluses in foreign currencies are invested in deposits when payments are expected to be made in that currency, mainly US dollars. These surpluses are also spread across various financial institutions to reduce dependency and credit risk.

With regard to financing, for transactions involving significant outlays, generally linked to business combinations, the Group evaluates the appropriate financing instrument. The Group's policy is to diversify debt from different sources (bond issues, bank loans from different banks or syndicated loans). There are also undrawn credit lines, as discussed in the first section.

Financing instruments include a series of covenants that, in the event of default, would result in a demand for immediate payment of these financial liabilities. The Group periodically assesses fulfilment therewith (as well as expected fulfilment, so that it may take corrective measures, if necessary). At 30 June 2024, all covenants are considered to be fulfilled, as mentioned in Note 18 to the condensed consolidated interim financial statements.

6. Risk factors

Noteworthy risk factors that may affect the achievement of business targets are as follows:

- Pressures related to price reductions, reimbursement conditions, contributions to the healthcare system or more restrictive regulations, which could increase with growing government budget deficits on the horizon and with a potential overall worsening of the macroeconomic conditions in European countries.
- Price increases in materials, transport and energy, as well as supply shortages, due to constant geopolitical and socio-economic threats.

- Unexpected climate changes and increasing risks of major natural disasters could accelerate the adoption of new regulations to reduce emissions, energy and water use and changes to increase climate resilience, thereby generating greater transition costs.
- Cyberattacks or security incidents that could allow access to confidential information or could cause a disruption of business activities.
- Impairment of intangible assets and goodwill due to lower-than-projected revenue streams.
- Inability to have a sufficiently balanced and differentiated R&D *pipeline* in its various phases, either with internal or external innovation, to nurture the portfolio of products.
- Difficulties in attracting and retaining talent.
- Delays in the implementation of new launches.

7. Treasury shares

The Parent Company has a liquidity contract with a financial intermediary, effective as from 4 March 2019, with the aim of favouring liquidity and stability of prices of the Company's shares, within the limits established by the General Shareholders' Meeting and by current regulations, in particular, Circular 1/2017, of 26 April, of the National Securities Market Commission (CNMV), on liquidity contracts. This contract means that, at 30 June 2024, the Parent Company holds treasury shares representing 0.09% of the share capital (0.09% on 31 December 2023) and an overall nominal value of €22.8 thousand (€23.0 thousand at 31 December 2023), which have been recognised in accordance with EU-IFRS. The average acquisition price of these shares was €9.7 per share. The treasury shares held by the Parent Company are intended to be traded on the market.

8. Trends for the year 2024

FY 2024 will be a key year from a commercial point of view, given that the launch of Ebglyss in different territories of Europe (although the main market for 2024 is expected to be Germany, where it was launched in December 2023) will be accompanied by the expected growth of the rest of the dermatology portfolio in Europe (Ilumetri, Wynzora and Klisyri, mainly), together with the growth of the recent acquisitions in Spain (Prometax and Physiorelax).

In terms of R&D activities, after FDA approval for extension of the Klisyri line in the United States in the second half of 2024, progress is also expected in the various projects that the group has under way in the early stages of development (linked to the agreements with Ichnos, Simcere, Etherna, Evotec, Novo Nordisk and Eloxx, among others). In addition, approval of Sarecycline by the Chinese regulatory authorities is also expected.

Finally, the Group's Management continues to focus on opportunistic M&A transactions that fit with the Group's business strategy, while always maintaining a prudent financial approach.

9. Capital structure. Significant shareholdings

The Parent Company's share capital as at 30 June 2024 is represented by 213,468,718 shares with a par value of €0.12, fully subscribed and paid up (209,393,724 shares as at 31 December 2023).

On 12 June 2024, a total of 4,074,994 new shares from the flexible dividend of the Parent Company were admitted to trading on the Barcelona, Madrid, Bilbao and Valencia stock exchanges. These shares were representative of the holders of 91.5% of the rights to be allotted shares at no charge, who opted to receive new shares instead of cash. Consequently, the share capital of the Parent Company following the bonus issue of shares increased by €488,999.28.

The Shareholders with significant holdings in the share capital of Almirall, S.A., both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, according to the information contained in the official records of the National Securities Market Commission (CNMV) as at 30 June 2024 and 31 December 2023, are as follows:

Name or company name of the direct shareholder	**% Interest 30/06/2024**	**% Interest 31/12/2023**
Grupo Plafin, S.A.	44.6%	44.5%
Grupo Corporativo Landon, S.L.	15.7%	15.6%
Norbel Inversiones	5.1%	5.1%
Wellington Management	2.9%	5.0%
Total	**68.3%**	**70.2%**

At 30 June 2024 and 31 December 2023, the Parent Company was not aware of any other holdings equal to or greater than 3% of the share capital or voting rights of the Parent Company, which, although less than the established percentage, would enable the exercise of significant influence over the Parent Company.

10. <u>Private agreements among shareholders and restrictions on transferability and voting</u>

There is a private agreement among shareholders, which has been duly notified to the CNMV, and the full text thereof can be consulted on the website www.almirall.com. It was concluded by Mr. Antonio Gallardo Ballart and Mr. Jorge Gallardo Ballart, and it regulates the concerted action of its signatories in Almirall, S.A. and the exercise of the voting rights inherent in their indirect participation in the Company through the company Grupo Plafin, S.A.U. and Todasa, S.A.U. (now Grupo Corporativo Landon, S.L.).

There are no restrictions set out in the Articles of Association on the free transferability of the Company's shares, nor are there any statutory or regulatory restrictions set out in the Articles of Association or in other regulations on voting rights.

11. <u>Management Bodies, Board</u>

Appointment of directors

Directors are appointed (i) at the proposal of the Appointments and Remuneration Committee, in the case of independent directors, and (ii) after a report from the Appointments and Remuneration Committee, in the case of other directors, by the General Shareholders' Meeting or by the Board of Directors in accordance with the provisions of the Spanish Capital Companies Act.

When a new director is appointed, they must follow the orientation programme for new directors established by the Parent Company, so that they can quickly acquire sufficient knowledge of the Parent Company and of its rules for corporate governance.

When designating external directors, the Board of Directors endeavours to ensure that candidates are chosen who have recognised solvency, competence and experience, given that great care must be taken when filling the posts of independent director provided for in Art. 6 of the Board Regulations.

Directors affected by proposals for re-election will abstain from taking part in deliberations and from any voting that deals with the Directors themselves.

Directors hold office for the term stipulated by the General Shareholders' Meeting, which must be the same for all of them and may not exceed four years. At the end of this term, they may be re-elected one or more times for periods of the same maximum duration.

Replacement of directors

Directors will leave office when the term for which they were appointed has elapsed or when so decided by the General Shareholders' Meeting in the exercise of the powers conferred upon it by law or by the Company's Articles of Association. In any case, the appointment of directors will end when the term has expired and the next General Meeting has been held or when the legal deadline for holding the meeting that must pass a resolution approving the previous year's accounts has elapsed.

The Board of Directors may only propose the dismissal of an independent director before expiry of the term established in the Articles of Association when there is just cause, as determined by the Board following a report from the Appointments and Remuneration Committee. In particular, just cause will be deemed to exist when the director has failed to comply with the duties inherent in their position or has incurred in any of the circumstances that prevent them from holding office as described in the definition of independent director established in the good corporate governance recommendations currently in force.

Directors affected by proposals for dismissal will abstain from taking part in the deliberations and voting on such proposals.

Directors must submit their resignation to the Board of Directors and, if the Board deems it appropriate, officially resign their post in the following cases:

a) When they leave the executive positions associated with their appointment as director.
b) When they find themselves in any of the situations resulting in incompatibility or prohibition as stipulated by law.
c) When they are seriously reprimanded by the Board of Directors for having breached their obligations as directors.

d) When their continued presence on the Board may jeopardise or damage the interests, credit or reputation of the Parent Company or when the reasons for which they were appointed cease to exist (for example, when a proprietary director sells their stake in the Parent Company).
e) In the case of independent directors, they may not remain in their posts for a continuous period of more than 12 years, and once this period has elapsed, they must submit their resignation to the Board of Directors and officially resign.
f) In the case of proprietary directors (i) when the shareholder they represent sells its entire stake and; likewise (ii) in the corresponding number, when this shareholder reduces its stake to a level that requires a reduction in the number of proprietary directors.

In the event that, due to resignation or for any other reason, a director leaves their post before the end of their term of office, they must explain the reasons in a letter to be sent to all the members of the Board.

Amendment of Articles of Association

The amendment of the Articles of Association is the responsibility of the General Shareholders' Meeting and is governed by Art. 160 of the Spanish Capital Companies Act and other concordant provisions, and there are no relevant specifications in this regard in the Articles of Association or the Regulations of the General Shareholders' Meeting.

Powers of Members of the Board of Directors

All the powers corresponding to the Board of Directors are permanently delegated in favour of the Chief Executive Officer of Almirall S.A. (Parent Company of the Group), according to a deed authorised on 11 May 2023 by the Notary Public of Barcelona, Mr. Enrique Viola Tarragona, acting in replacement of and for the notarial records of his colleague of the same city, Ms. Blanca Pardo García.

12. Significant agreements

There are no significant agreements, either in relation to changes of control of the Parent Company or between the Parent Company and its Directors and Management or Employees, regarding compensation for resignation, dismissal or takeover bids.

13. Subsequent events

No significant events have occurred subsequent to the end of the reporting period as at the date of preparation of this consolidated interim management report.